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A B S T R A C T
Background
The role of low-level laser therapy (LLLT) in the management of carpal tunnel syndrome (CTS) is controversial. While some trials
have shown distinct advantages of LLLT over placebo and some other non-surgical treatments, other trials have not.
Objectives
To assess the benefits and harms of LLLT versus placebo and versus other non-surgical interventions in the management of CTS.
Search methods
On 9 December 2016 we searched CENTRAL, MEDLINE, Embase, and Science Citation Index Expanded for randomised controlled
trials (RCTs). We also searched clinical trial registries for ongoing studies. We checked the references of primary studies and review
articles, and contacted trial authors for additional studies.
Selection criteria
We considered for inclusion RCTs (irrespective of blinding, publication status or language) comparing LLLT versus placebo or non-
surgical treatment for the management of CTS.
Data collection and analysis
Two review authors independently identified trials for inclusion and extracted the data. For continuous outcomes, we calculated the
mean difference (MD) or standardised mean difference (SMD) with a 95% confidence interval (CI) using the random-effects model,
calculated using Review Manager. For dichotomous data, we reported risk ratio (RR) and 95% CI.
Main results
We identified 22 trials randomising 1153 participants that were eligible for inclusion; nine trials (525 participants, 256 randomised to
LLLT) compared LLLT with placebo, two (150 participants, 75 randomised to LLLT) compared LLLT with ultrasound, one compared
LLLT with placebo and LLLT with ultrasound, two compared LLLT with steroid injection, and one trial each compared LLLT with
other non-surgical interventions: fascial manipulation, application of a pulsedmagnetic field, transcutaneous electrical nerve stimulation
(TENS), steroid injection, tendon gliding exercises, and applying a wrist splint combined with non-steroidal anti-inflammatory drugs.
Three studies compared LLLT as part of multiple interventions. Risk of bias varied across the studies, but was high or unclear in
most assessed domains in most studies. Most studies were small, with few events, and effect estimates were generally imprecise and
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inconsistent; the combination of these factors led us to categorise the quality of evidence for most outcomes as very low or, for a small
number, low.
At short-term follow-up (less than three months), there was very low-quality evidence for any effect over placebo of LLLT on CTS for
the primary outcome of Symptom Severity Score (scale 1 to 5, higher score represents worsening; MD -0.36, 95% CI -0.78 to 0.06)
or Functional Status Scale (scale 1 to 5, higher score represents worsened disability; MD -0.56, 95% CI -1.03 to -0.09). At short-term
(less than three months) follow-up, we are uncertain whether LLLT results in a greater improvement than placebo in visual analogue
score (VAS) pain (scale 0 to 10, higher score represents worsening; MD -1.47, 95% CI -2.36 to -0.58) and several aspects of nerve
conduction studies (motor nerve latency: higher score represents worsening; MD -0.09 ms, 95% CI -0.16 to -0.03; range 3.1 ms to
4.99 ms; sensory nerve latency: MD -0.10 ms, 95% CI -0.15 to -0.06; range 1.8 ms to 3.9 ms), as the quality of the evidence was very
low. When compared with placebo at short-term follow-up, LLLT may slightly improve grip strength (MD 2.58 kg, 95% CI 1.22 to
3.95; range 14.2 kg to 25.23 kg) and finger-pinch strength (MD 0.94 kg, 95% CI 0.43 to 1.44; range 4.35 kg to 5.7 kg); however,
the quality of evidence was low. Only VAS pain and finger-pinch strength results reached the minimal clinically important difference
(MCID) as previously published.
We are uncertain about the effect of LLLT in comparison to ultrasound at short-term follow-up for improvement in VAS pain (MD
2.81, 95% CI 1.21 to 4.40) and motor nerve latency (MD 0.61 ms, 95% CI 0.27 to 0.95), as the quality of evidence was very low.
When compared with ultrasound at short-term follow-up, LLLT may result in slightly less improvement in finger-pinch strength (MD
-0.71 kg, 95% CI -0.94 to -0.49) and motor nerve amplitude (MD -1.90 mV, 95% CI -3.63 to -0.18; range 7.10 mV to 9.70 mV);
however, the quality of evidence was low.
There was insufficient evidence to assess the long-term benefits of LLLT versus placebo or ultrasound. There was insufficient evidence
to show whether LLLT is better or worse in the management of CTS than other non-surgical interventions. For all outcomes reported
within these other comparisons, the quality of evidence was very low.
There was insufficient evidence to assess adverse events, as only one study reported this outcome.
Authors’ conclusions
The evidence is of very low quality and we found no data to support any clinical effect of LLLT in treating CTS. Only VAS pain
and finger-pinch strength met previously published MCIDs but these are likely to be overestimates of effect given the small studies
and significant risk of bias. There is low or very low-quality evidence to suggest that LLLT is less effective than ultrasound in the
management of CTS based on short-term, clinically significant improvements in pain and finger-pinch strength.
There is insufficient evidence to support LLLT being better or worse than any other type of non-surgical treatment in the management
of CTS. Any further research of LLLT should be definitive, blinded, and of high quality.
P L A I N L A N G U A G E S U M M A R Y
Laser therapy for carpal tunnel syndrome
Review question
What are the effects of low-level laser therapy (LLLT) for the treatment of carpal tunnel syndrome (CTS) when compared to inactive
treatment or other non-surgical treatments? What are the short-term and long-term benefits? Are there any harmful effects?
Background
CTS is a condition where one of the main nerves in the wrist is compressed. The underlying cause is often unknown. CTS can cause
pain, tingling, and numbness in the hand. It is more common as we age and women are more often affected than men. CTS can be
treated with surgery, but this is not without risk. For people who do not wish to have surgery, or have a long wait until their operation,
other treatments are available. LLLT is one of the non-surgical treatments available to manage CTS. Use of LLLT is controversial, as
some research has shown it to be of benefit whereas other research has not.
Search date
The evidence is current to December 2016.
Study characteristics
2Low-level laser therapy for carpal tunnel syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We collected and analysed all relevant studies to answer the review question. We found 22 clinical trials that assessed the safety and
benefit of LLLT when compared to a placebo (pretend treatment) or another non-surgical treatment for CTS. Non-surgical treatments
included ultrasound (delivery of sound waves to relieve pain), fascial manipulation (massage of deep connective tissue), application
of a pulsed magnetic field, transcutaneous electrical nerve stimulation (TENS; delivery of electrical current through skin to nerves),
steroid injection, tendon gliding exercises (to improve the movement of the nerve), and applying a wrist splint combined with non-
steroidal anti-inflammatory drugs (pain killers that reduce inflammation). The trials involved 1153 participants. Most of these studies
had weaknesses that could have compromised their results and caused them to overestimate or underestimate benefits or harms.
Quality of the evidence
We assessed the quality of the evidence as low quality or very low quality, due to poorly conducted studies, issues with study designs
including lack of blinding (participants or assessor may have known which treatment was given and thereby anticipated the results),
dissimilar results across studies, and not enough participants and therefore data.
Key results
We are uncertain whether LLLT improves symptoms of CTS more than placebo in the short term as the quality of the evidence is very
low. Similarly, we are uncertain whether LLLT is less effective than ultrasound treatment in the short term as the quality of evidence Is
very low. We do not know whether LLLT is better or worse than any other non-surgical treatment as evidence is lacking. There is also
not enough evidence to draw any conclusions about any long-term benefits or harms of LLLT. There is not enough evidence to draw
any conclusions about the adverse events a participant may experience from using LLLT. We need more well-designed, well-conducted
research to find out how effective and safe LLLT is in the management of CTS.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low- level laser therapy compared to placebo for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with low- level
laser therapy
Overall improvement in
CTS: SSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
2.03
MD 0.36 lower
(0.78 lower to 0.06
higher)
- 327
(7 RCTs)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: SSS: long term
Scale f rom: 1 to 5
Follow-up: mean 12
months
The mean overall im-
provement (as mea-
sured by SSS) long term
was 2
MD 0.2 higher
(0.54 lower to 0.94
higher)
- 25
(1 RCT)
⊕©©©
Very low 1,3,4,5
-
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean FSS short
term (< 3 months) was
2.16
MD 0.56 lower
(1.03 lower to 0.09
higher)
- 159
(5 RCTs)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term
Scale f rom: 1 to 5
Follow-up: mean 12
months
The mean FSS long
term was 2.3
MD 0.1 lower
(0.73 lower to 0.53
higher)
- 25
(1 RCT)
⊕©©©
Very low 1,3,4,5
-
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Adverse events - - - - - No adverse events re-
ported in any trial.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: men dif ference; RCT: randomised controlled trial; SSS: Symptom Severity Score.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Lit t le overlap of conf idence intervals and heterogeneity in magnitude of ef fect.
3 Total sample size under 400 in total in both groups.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
5 Only one trial.
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B A C K G R O U N D
Description of the condition
Carpal tunnel syndrome (CTS) is a neuromuscular condition in
which the median nerve becomes compressed at the level of the
wrist secondary to increased pressure within the carpal tunnel
(Keith 2009; Kerwin 1996). Disease processes or injury that in-
crease the volume of the contents of the tunnel, including tumour,
inflammation, oedema, andobesity, will elevate the pressurewithin
the carpal tunnel. Conditions that reduce the volume of the tunnel
(e.g. rheumatoid arthritis or previous fracture) can also predispose
to CTS. Any disease that predisposes to peripheral neuropathy
(damage to the nerves) can render the median nerve more suscep-
tible to CTS. The cause is most commonly idiopathic (unknown),
but a number of conditions are associated with CTS including
pregnancy, untreated hypothyroidism, acromegaly, mucopolysac-
charidosis, diabetes, amyloidosis, space-occupying lesions in the
tunnel, and obesity. Many other associations have been suggested
(Kerwin 1996).
The symptoms of CTS include pain and paraesthesia (abnormal
sensation, typically tingling) in the sensory distribution of theme-
dian nerve in the wrist and hand (the thumb, index, and middle
fingers, and radial half of the ring finger) (Rempel 1998; Szabo
1994). Wasting of the thenar (thumb) muscles can occur in ad-
vanced cases (Szabo 1994). CTS is the most common type of en-
trapment neuropathy (a disease process caused by direct pressure
on a single nerve - in this case, the median nerve), with a preva-
lence of 3.8% for clinically diagnosed cases and 2.7% for electro-
physiologically confirmed cases, when measured across a sample
of 170,000 of the general population in Sweden (Atroshi 1999).
Women are more commonly affected than men and its incidence
increases with age: women between the ages of 40 and 60 years
experience CTS four times more commonly than men (Atroshi
1999). The most commonly used diagnostic test is nerve conduc-
tion studies (NCS). This demonstrates slowing of median nerve
conduction and, in severe cases, evidence of axonal loss at the carpal
tunnel. NCS are considered themost reliable available, though not
perfect, diagnostic test. Median sensory and motor NCS are valid
and reproducible clinical laboratory studies that confirm a clinical
diagnosis of CTS with a high degree of sensitivity and specificity
(Jablecki 1993).
CTS can be treated using surgical or non-surgical interventions.
Surgical interventions are usually offered to people who have per-
sistent CTS symptoms, severe sensory disturbance, or thenarmus-
cle wasting (AAN 1993). Non-surgical interventions can be of-
fered to people who experience intermittent symptoms of mild
to moderate CTS or to people who do not wish to have surgery,
or as a temporary measure for people awaiting surgery (Atroshi
1999;DeKrom1992).CochraneReviews onCTShave concluded
the benefit of surgical interventions (Scholten 2007 (part update
in Vasiliadis 2014); Verdugo 2008), steroid injections (Marshall
2007), and splints (Page 2012a). Many other non-surgical inter-
ventions have been suggested, for most of which there are insuffi-
cient high-quality studies for a conclusion to be drawn on efficacy.
Description of the intervention
LLLT is the application of red and near infrared light, typically
in the 600 nm to 1000 nm wavelength spectrum, to biological
tissues to achieve therapeutic outcomes. It emits no heat, sound,
or vibration. Instead of producing a thermal effect, LLLT may act
by non-thermal or photochemical reactions in cells. It can be pro-
duced by laser or high-intensity light-emitting diodes, which are
placed against the skin of the painful area. LLLT devices typically
deliver a power density in the ranges from 10 mW to 500 mW
(Bjordal 2003).
There is a lack of reports of adverse events in relation to LLLT
(Chung 2012). Temporary discomfort at the application site has
been reported (Fusakul 2014). A hypothesised potential adverse
effect includes stimulating proliferationof existing skin cancer cells
(Frigo 2009).
Description of the comparators in this review
Splinting involves immobilisation of the wrist in a neutral position
(where the wrist is in straight alignment with the forearm: no flex-
ion (palm toward wrist), extension (back of hand raised), radial or
ulnar deviation (twisting)) for a specified period of time. Pressure
on the carpal tunnel is increased in positions of wrist flexion and
extension. With the wrist held in a neutral position, pressure on
the carpal tunnel is reduced, which can lead to an improvement
in symptoms (Gelberman 1984). One Cochrane systematic re-
view concluded that there is limited evidence that a splint worn at
night is more effective than no treatment in the short term (Page
2012a). However, the authors noted a lack of participant blinding
and unclear allocation concealment within studies and suggested
interpretation of the findings with caution. There was insufficient
evidence regarding the effectiveness and safety of one splint de-
sign or wearing regimen over others, and of splint over other non-
surgical interventions for CTS.
Non-steroidal anti-inflammatory drugs (NSAIDs) work by in-
hibiting an enzyme called cyclo-oxygenase, which is involved in
the production of prostaglandins that contribute to the produc-
tion of inflammation and pain. Reduction of these prostaglandins
can help relieve symptoms related to inflammation and mild to
moderate pain (Labelle 1997).
Therapeutic ultrasound involves delivering sound waves, via ap-
plication of a round-headed instrument to the skin of the painful
area, that are absorbed by the underlying tissues to help relieve pain
and lessen disability. Its exact mechanism of action is contested.
Early experimental work suggested a thermal anti-inflammatory
and tissue-stimulating effect (Hong 1988). Newer research sug-
gests that it does not have an anti-inflammatory effect but accel-
6Low-level laser therapy for carpal tunnel syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
erates the process of resolution of oedema within the carpal tun-
nel, with subsequent reduction in carpal tunnel pressures (Yildiz
2011). One Cochrane systematic review concluded that there was
only poor-quality evidence from very limited data to suggest that
ultrasound may be more effective than placebo for either short-
term or long-term symptom improvement in people with CTS
(Page 2013). When examining its effects compared to other non-
surgical interventions, such as splinting or laser therapy, the review
concluded that there is insufficient evidence to support the use
of ultrasound as a treatment with greater efficacy when compared
to other non-surgical interventions for CTS. The review exam-
ined one trial looking at ultrasound versus laser therapy (Bakhtiary
2004), and one trial comparing ultrasound in conjunction with
applying a wrist splint to laser therapy with applying a wrist splint
(Dincer 2009).
Transcutaneous electrical nerve stimulation (TENS) delivers elec-
trical stimulation to the underlying peripheral nerves via electrodes
placed over the intact skin surface. This electrical stimulation to
primary sensory afferent fibres activates inhibitory interneurons,
blocking the transmission of pain signals from nociceptive pain
fibres. This action serves to dampen the perception of pain (Sluka
2003).
Corticosteroid injections are administered within the carpal tun-
nel to provide symptomatic improvement. The mechanism of ac-
tion is poorly understood. One Cochrane systematic review con-
cluded that local corticosteroid injection provides greater clini-
cal improvement in symptoms one month after injection com-
pared to placebo; relief beyond one month was not demonstrated
(Marshall 2007). The review also included comparisons of steroid
injection to other non-surgical interventions. This included one
trial comparing steroid injection to laser therapy, which showed
steroid injection did not improve clinical outcome compared to
laser therapy at six months (Lucantoni 1992).
Fascial manipulation is a manual therapy that focuses on massage
of deepmuscular fascia. The intervention is hypothesised to stretch
surrounding fascia to reduce pressure on the median nerve within
the carpal tunnel and therefore provide symptomatic relief (Pratelli
2015).
Tendon-gliding exercises involve taking themedian nerve through
its available range of motion in an attempt to improve the excur-
sion of the nerve, reducing symptoms by decreasing adhesions, fa-
cilitating venous return, and facilitating dispersal of oedema in the
carpal tunnel (Atya 2011).OneCochrane systematic review exam-
ined the efficacy of mobilisation interventions, including tendon
gliding exercises (TGE) (Page 2012b). The review concluded that
there is limited and very low-quality evidence of benefit for mobil-
isation interventions for CTS and that the use of this type of non-
surgical intervention should be based on the clinician’s expertise
in being able to deliver these treatments and patient preferences.
Pulsed magnetic field (PMF) therapy is based on the principle of
an interaction between non-ionising electromagnetic fields and
biological systems to relieve pain. It is hypothesised that treatment
effectsmay be related to increased local cellular activity, orientation
of collagenfibres, and vasodilation of blood vessels (Quittan 2000).
How the intervention might work
LLLT is applied with the aim of reducing inflammation and pro-
viding symptomatic relief for acute and chronic pain. It is thought
to produce an analgesic effect by lowering levels of pain mediators
such as prostaglandins, beta-endorphins, interleukin 1-beta and
tumour necrosis factor-alpha, as well as by improving local micro-
circulation (Bingol 2005; Brosseau 2005; Jablecki 1993).
The biochemicalmechanisms underlying the therapeutic effects of
LLLT are not well-established (Chung 2012). It is suggested that
infrared light is absorbed by cellular chromophores on mitochon-
dria (Greco 1989) to increase adenosine triphosphate (ATP) pro-
duction (Karu 1999), with resultant modulation of reactive oxy-
gen species and induction of transcription factors (Chen 2011).
Several transcription factors are indicated: redox factor-1, depen-
dent activator protein-1, nuclear factor kappa B, p53, activating
transcription factor/cAMP-response element-binding protein, hy-
poxia-inducible factor, and hypoxia-inducible factor (HIF)-like
factor (Chen 2011). The downstream effects of the protein syn-
thesis following activation of these transcription factors are hy-
pothesised to include increased cell proliferation and migration;
modulation in the levels of cytokines, growth factors, and inflam-
matory mediators; and increased tissue oxygenation (Karu 2005).
Why it is important to do this review
Surgical treatment options for people with CTS have been exam-
ined in other Cochrane Reviews: Surgical treatment options for
CTS (Scholten2007), and the effect of surgical versus non-surgical
treatment (Verdugo 2008). Cochrane systematic reviews of local
steroid injection (Marshall 2007), splinting (Page 2012a), thera-
peutic ultrasound (Page 2013), mobilisation interventions (Page
2012b), and ergonomic interventions (O’Connor 2012) for CTS
already exist, and up-to-date Cochrane systematic reviews of other
non-surgical interventions for CTS are required.
A number of placebo-controlled studies have reported that LLLT
can alleviate clinical symptoms and improve electrophysiological
parameters (as measured in NCS) in people with CTS (Chang
2008; Evcik 2007; Shooshtari 2008; Naeser 2002), while other
studies have not found a difference between LLLT and placebo
(Irvine 2004; Tascioglu 2012). LLLT has been studied as a treat-
ment in other painful conditions. One Cochrane systematic re-
view investigating the use of LLLT as a treatment in rheumatoid
arthritis concluded that LLLT could be considered for short-term
treatment for relief of pain and morning stiffness for people with
rheumatoid arthritis (Brosseau 2005). However, a further review
for its use in low back pain concluded that evidence was insuffi-
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cient to either support or refute its effectiveness (Yousefi-Nooraie
2008).
This systematic review andmeta-analysis of randomised controlled
trials (RCTs) aimed to address whether LLLT is of benefit in the
non-surgical treatment of people with CTS. We aimed to assess
the effectiveness and safety of LLLT compared with placebo or
other non-surgical modalities, namely splinting, therapeutic ultra-
sound, and corticosteroid injection. More specifically, we aimed to
evaluate the relative impact of LLLT in relieving symptoms, pro-
ducing functional recovery (return to work and daily activities),
and assessing adverse events compared to other treatments.
O B J E C T I V E S
To qualitatively and quantitatively assess the clinical efficacy and
safety of LLLT, when compared to placebo or other non-surgical
treatment, in the management of CTS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We conducted this systematic review and meta-analysis in accor-
dance with the PRISMA reporting guidelines for the conduct of
meta-analysis of interventional trials (Liberati 2009). We submit-
ted a prospective systematic review and meta-analysis protocol
to PROSPERO (www.crd.york.ac.uk/PROSPERO; registration
number: CRD42016037433) prior to commencement (Rankin
2016).
We included all RCTs or quasi-RCTs that compared LLLT with
placebo or any non-surgical intervention, irrespective of language,
blinding, publication status, sample size, or whether the trials were
adequately powered.
Types of participants
People with a diagnosis of CTS, as defined by the authors of each
study; we excluded people with a history of previous surgery for
CTS. There were no restrictions placed on the use of LLLT while
awaiting surgery or as a standalone treatment.
Types of interventions
All LLLT interventions (with differing wavelength, intensity, and
duration) versus placeboor non-surgical treatments were included.
All non-surgical treatments (regardless of dose, duration, etc.) were
eligible for inclusion. We excluded trials that assessed the effects
of LLLT in combination with another intervention, which was
compared to a different intervention or the additional intervention
without placebo LLLT (so the additional effect of LLLT could not
be determined). We excluded trials comparing LLLT to surgical
treatment.
Types of outcome measures
Primary outcomes
• Overall improvement in CTS, as measured by the patient-
reported Symptom Severity Score (SSS) and Functional Status
Scale (FSS) (Levine 1993). An increase in SSS or FSS represents
increased severity of symptoms or worsened disability.
Secondary outcomes
• Visual analogue score (VAS) pain (McCormack 1988). An
increase in VAS pain represents increased severity of pain.
• Strength measured by dynamometry (grip strength and
finger-pinch strength).
• Nerve conduction studies (NCS). An increase in amplitude
or velocity, or a decrease in latency, represents an improvement in
nerve conduction.
• Adverse events, defined as the number of participants with
at least one adverse event, or serious adverse events, defined as
the number of participants with at least one serious adverse
event. We will distinguish adverse and serious adverse events in
accordance with International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use
(ICH) Good Clinical Practice definitions.
• Any other measure of improvement in symptoms or
function (e.g. Disabilities of the Arm, Shoulder and Hand
(DASH) questionnaire (Hudak 1996), overall improvement
questionnaires, health-related quality of life, or time to return to
work/resume activities of daily living).
For all outcomes, we considered both short-term effects (three
months or less) and long-term effects (greater than three months).
If multiple time points were reported, we considered the latest
measurement within three months as ’short-term’. We considered
the longest follow-up available, if greater than three months, as
’long-term’.
Search methods for identification of studies
Electronic searches
On 9 December 2016, we searched the following databases for
eligible RCTs:
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• Cochrane Register of Controlled Trials (CENTRAL; 2016,
Issue 11);
• MEDLINE;
• Embase;
• Web of Science Core Collection
We searched the following databases for ongoing studies:
• US National Institutes for Health clinical trials registry (
www.ClinicalTrials.gov);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (www.who.int/ictrp/en/).
We presented the search strategy for each database and clinical
trial registries in Appendix 1; Appendix 2; Appendix 3; Appendix
4; Appendix 5; Appendix 6. We searched all databases from their
inception to 9 December 2016. We imposed no restrictions on
the language of publication.
Searching other resources
We searched the reference lists of all primary studies and review
articles for additional references. We contacted trial authors to
identify further studies. For included studies published in full text
on PubMed (www.ncbi.nlm.nih.gov/pubmed), we also searched
for errata or retractions.
Data collection and analysis
Selection of studies
The review authors identified and excluded duplicate references.
Two review authors (IR andHS) independently screened titles and
abstracts of all studies identified by the search strategies and ex-
cluded studies that did not meet the inclusion criteria. They inde-
pendently screened the full text of the study reports of the remain-
ing studies. They identified studies for inclusion and recorded rea-
sons for any exclusionof the ineligible studies in theCharacteristics
of excluded studies table. They resolved any disagreements through
discussion and by consulting with a third review author (HR). We
completed a PRISMA flow diagram (Figure 1).
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Figure 1. Study flow diagram. LLLT: low-level laser therapy.
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Data extraction and management
Two review authors (IR and HS) independently extracted study
characteristics and outcome data from included studies using a
standardised predesigned data extraction form. The data extrac-
tion form included information on setting, population, inclusion
and exclusion criteria, interventions, comparison, and outcomes.
We made notes on funding, baseline differences, and any notable
conflicts of interest of trial authors. We resolved any disagreements
through discussion or, if required, through consultation with a
third review author (HR). We contacted trial authors when we
required further information. One review author (IR) transferred
the data into Review Manager 5 (RevMan 2014), and another
review author (HS) checked the outcome data entries. We present
details in the Characteristics of included studies table.
Assessment of risk of bias in included studies
Two review authors (IR and HS) independently assessed the risk
of bias for each trial identifying the key trial reporting components
using the CONSORT statement (Schulz 2011), and using the
Cochrane ’Risk of bias’ tool, described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We assessed
risk of bias based on information extracted from the reports of
the included studies for the following: random sequence gener-
ation, allocation concealment, blinding of participants and per-
sonnel, blinding of observers, incomplete outcome data, selective
outcome reporting, and other sources of bias (e.g. inappropriate
unit of analysis). We rated each item as at low, unclear, or high
risk of bias. We summarised the ’Risk of bias’ judgements across
different studies for each of the domains listed. We resolved any
discrepancies through discussion and by consulting with a third
review author (HR). Table 8.5.c of the Cochrane Handbook for
Systematic Reviews of Interventions details the criteria for judging
the risk of bias in each study (Higgins 2011).
Measures of treatment effect
We used Review Manager 5 to perform data analysis (RevMan
2014). We pooled results of studies with similar characteristics
(participants, interventions, outcomemeasures, and timing of out-
come measures) to provide estimates of the efficacy of LLLT for
CTS.We took the different interventions being compared into ac-
count in our data synthesis; for example, we analysed LLLT versus
splinting studies separately from LLLT versus ultrasound studies.
If a single study reported multiple trial arms, we included only
the arms in which the interventions were LLLT and a comparator.
When we could not combine data in the form of a meta-analysis,
we presented a narrative synthesis of results. We expressed results
for binary outcomes as risk ratios (RRs) with 95% confidence in-
tervals (CIs). We expressed results for continuous outcomes (func-
tional status, i.e. FSS; disability, i.e. DASH; grip strength; finger-
pinch strength; NCS) as mean differences (MDs) with 95% CIs
where the same scale was used, and as standardised mean differ-
ences (SMDs) with 95% CIs where different scales were used. Or-
dinal outcomes (questionnaires measuring overall improvement
with ratings such as ’improved’ or ’not improved’) were treated
and analysed as continuous outcomes. We planned to report the
results of time-to-event outcomes (time to return to work and time
to return to activities of daily living) using hazard ratios, but the
included trials did not report these outcomes.
Unit of analysis issues
Where trialists had made inappropriate adjustments for bilateral
involvement of wrists, we carried out a sensitivity analysis to ac-
count for a clustering unit-of-analysis error. Because results for
wrists from the same person are not independent (i.e. they are
likely to be correlated), an analysis that fails to take bilateral cases
into account is likely to produce inappropriately narrow CIs.
In these circumstances (i.e. where studies included bilateral cases),
we intended to adjust the summary effect estimate for each out-
come for the intracluster correlation coefficient (ICC). As the ICC
was not available from any included trial, we were unable to per-
form this adjustment. To assess for differences in the interpretation
of effect estimate that may have occurred because of this unit-of-
analysis error, we performed a sensitivity analysis utilisingmultiple
different ICCs. These ranged from 0.01 to 1.00. These analyses
are discussed at the relevant sections of the results. The presented
’Summary of findings’ tables and forest plot analyses were unable
to include adjustment for clustering effects from unit-of-analysis
errors (as the correct ICC is unknown), and so presented original
trial author data.
Dealing with missing data
We reported per-protocol analysis. We were unable to perform
multiple imputation analysis to account for missing data due to
postrandomisation dropouts because no authors reported this or
presented individual participant data. We contacted trial authors
for further information; however, this was not provided.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the participants’
characteristics and the methodology across studies. We assessed
statistical heterogeneity using the Chi² test with significance set
at P = 0.10 and measured the quantity of heterogeneity using the
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I² statistic (Higgins 2002). We interpreted the I² statistic using
the following ranges as an approximate guide: 0% to 40% might
not be important heterogeneity, 30% to 60% might represent
moderate heterogeneity, 50% to 90% might represent substantial
heterogeneity, and 75% to 100% might represent considerable
heterogeneity (Deeks 2011).
Assessment of reporting biases
For outcomes that included data from at least 10 studies, we in-
tended to draw funnel plots to assess the association between study
size and effect size. Where appropriate, we would also have used
these funnel plots to distinguish between reporting bias and other
causes of asymmetry (Peters 2008). However, sufficient studies
were not available to conduct these analyses.
Data synthesis
We carried out meta-analyses of pooled results using a random-
effects model, as this was more conservative than the fixed-effect
model. We used the DerSimonian and Laird method in the meta-
analysis of binary outcomes (DerSimonian 1986) and the inverse
variance method for continuous outcomes.
’Summary of findings’ tables
We included ’Summary of findings’ tables for all comparisons for
which data were available. We presented the following outcomes:
• Overall improvement (as measured by SSS) short term (less
than three months);
• Overall improvement (as measured by SSS) long term;
• FSS short term (less than three months);
• FSS long term;
• Adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence (studies that con-
tributed data for a prespecified outcome). We used methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We used GRADEpro GDT software (gradepro.org/). We
provided footnotes to explain decisions to downgrade or upgrade
the quality of evidence.
We did not produce a ’Summary of findings’ table for comparisons
if there were no data for any prespecified outcome.
Subgroup analysis and investigation of heterogeneity
We intended to perform subgroup analyses for sex, age, severity of
CTS symptoms, and studies at high versus studies at low risk of
bias. However, sufficient information was not available for these
subgroup analyses.
Sensitivity analysis
AsdescribedunderUnit of analysis issues, we performed sensitivity
analyses utilising multiple different ICCs to assess for differences
in interpretation of effect estimate. The ICCs ranged from 0.01 to
1.00. The findings are commented upon in each relevant section
of the results.
We performed a fixed-effect analysis to investigate small-study
effects.
R E S U L T S
Description of studies
Results of the search
We identified 247 references through electronic searches of CEN-
TRAL (64 papers), MEDLINE (18 papers), Embase (90 papers),
and Web of Science (75 papers). We excluded 118 duplicates
and 99 irrelevant references through reading the abstracts. We
retrieved 30 references for further assessment. We identified no
further studies through scanning reference lists of the identified
RCTs. We included 22 trials in the extraction of data for analysis
(Aigner 1999; Atya 2011; Bakhtiary 2004; Casale 2013; Chang
2008; Dakowicz 2011; Dincer 2009; Ekim 2007; Evcik 2007;
Fusakul 2014; Irvine 2004; Jiang 2011; Lazovic 2014; Lucantoni
1992; Pratelli 2015; Rayegani 2013; Rodrigues 2013; Saeed 2012;
Shooshtari 2008; Soltani 2013; Tascioglu 2012; Tikiz 2013). We
excluded eight studies for the reasons listed in the Characteristics
of excluded studies table (Barbosa 2016; Branco 1999; Kotb 2014;
Montes-Molina 2011; Naeser 2002; Padua 1999; Tamam 2012;
Yagci 2009). The PRISMA flow diagram is shown in Figure 1.
Included studies
For each included trial, we collected details about the setting,
population, inclusion and exclusion criteria, intervention, com-
parison, and outcomes (Characteristics of included studies table).
All included trials were completed. Nine trials compared LLLT
versus placebo, two compared LLLT versus ultrasound, one trial
compared LLLT versus placebo and LLLT versus ultrasound, two
compared LLLT versus steroid injection, and one each compared
LLLT versus fascial manipulation, LLLT versus PMF, LLLT versus
TENS, LLLT versus wrist splint with NSAIDs, and LLLT versus
TGEs. Three trials measured LLLT as part of multiple interven-
tions: one compared LLLT, applying a wrist splint, and vitamin B6
versus placebo LLLT, applying a wrist splint, and vitamin B6, one
compared LLLT and applying a wrist splint versus placebo LLLT
and applying a wrist splint, and one compared LLLT and applying
a wrist splint versus ultrasound and applying a wrist splint. All
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trials measured short-term outcomes. One trial measured long-
term outcomes (at one year) for placebo and for ultrasound (Tikiz
2013), and one trial measured long-term outcomes (at sixmonths)
for steroid injection (Lucantoni 1992).
Excluded studies
TheCharacteristics of excluded studies table presents details about
the reason for exclusion of the eight studies excluded after full-text
review. Four studies used LLLT plus another intervention which
was compared to the additional intervention without placebo or
a different intervention for CTS (so the additional effect of LLLT
could not be determined), two included participants with a history
of previous surgery for CTS, one was not a RCT, and one had
insufficient information to assess eligibility.
Risk of bias in included studies
The ’Risk of bias’ summary figure (Figure 2) shows the risk of bias
in included trials, and further information, including a quote or
comment to support judgement, are available in the ’Risk of bias’
tables within the Characteristics of included studies table. Risk of
bias varied across the studies, but was generally high in most do-
mains. All studies were small, ranging from 15 to 100 participants
and therefore an overestimation of any effect was likely.
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Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Five trials reported an adequate method of random sequence gen-
eration with subsequent adequate allocation concealment. Only
three LLLT versus placebo trials, and none of the LLLT versus
ultrasound trials adequately reported the method of participant
blinding. Six of the seven other non-surgical intervention studies
were unblinded, and in the final trial the blinding methodology
was unclear. Two of the combination trials did not have adequate
blinding and the final trial was unclear. Lack of participant blind-
ing may have influenced the self-reported outcomes of VAS pain,
SSS, and FSS. Two trials did not perform blinding of outcome
assessment, and a further nine trials were at unclear risk of bias.
Attrition bias was unclear for four trials as therewas insufficient in-
formation to assess whether themissing datamechanismwas likely
to have introduced bias in the estimate of effect and no methods
were used to handle missing data, such as multiple imputation
analysis. Some type of reporting bias was present in three studies
and unclear in 10 studies. In particular, two trials appeared to be at
risk of selective outcome reporting where the SSS was reported but
not FSS - both are present within the same questionnaire (Evcik
2007; Jiang 2011). Unit-of-analysis errors occurred in seven trials
that did not account for clustering due to inclusion of participants
with bilateral wrists and separate units of allocations to each wrist
(Bakhtiary 2004; Dincer 2009; Fusakul 2014; Lucantoni 1992;
Pratelli 2015; Soltani 2013; Tikiz 2013).
Allocation
Five trials reported an adequate method of random sequence
generation with subsequent adequate allocation concealment (
Bakhtiary 2004; Irvine 2004; Lazovic 2014; Saeed 2012; Tascioglu
2012). One trial was at high risk of selection bias with inadequate
random sequence generation and allocation concealment (Tikiz
2013), and one trial was at high risk of bias due to inadequate
random sequence generation (Pratelli 2015). The remaining in-
cluded trials were of unknown risk of bias from random sequence
generation, allocation concealment, or both.
Blinding
Blinding of participants and personnel was at high risk of bias
in nine studies (Atya 2011; Dakowicz 2011; Dincer 2009; Ekim
2007; Lucantoni 1992; Pratelli 2015; Rayegani 2013; Rodrigues
2013; Soltani 2013), as was blinding of outcome assessors in two
studies (Aigner 1999;Rayegani 2013). Therewas low risk of bias in
three studies where there was blinding of participants, personnel,
and outcome assessors (Evcik 2007; Irvine 2004; Lazovic 2014).
The remaining trials were of unknown risk of bias in one or both
domains of blinding (of personnel and participants, or of outcome
assessment).
Incomplete outcome data
Attrition bias was unclear for four trials as there was insufficient
information to assess whether the missing data mechanism was
likely to have introduced bias in the estimate of effect and the
trialists did not usemethods (such asmultiple imputation analysis)
to handle missing data (Dincer 2009; Fusakul 2014; Jiang 2011;
Lucantoni 1992). The remaining trials were all at low risk of bias.
Selective reporting
Three studies were at high risk of reporting bias (Dincer 2009;
Evcik 2007; Jiang 2011), and 9 were at unclear risk (Aigner 1999;
Lazovic 2014; Lucantoni 1992; Rodrigues 2013; Rayegani 2013;
Saeed 2012; Soltani 2013; Shooshtari 2008; Tikiz 2013). The
remaining trials were at low risk of bias.
Other potential sources of bias
Nine trials were free of vested interest bias (Bakhtiary 2004; Chang
2008; Dincer 2009; Ekim 2007; Fusakul 2014; Irvine 2004; Jiang
2011; Lazovic 2014; Tikiz 2013). The remaining trials were at
unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Low-level
laser therapy compared to placebo for carpal tunnel syndrome;
Summary of findings 2 Low-level laser therapy compared to
ultrasound for carpal tunnel syndrome; Summary of findings
3 Low-level laser therapy compared to fascial manipulation for
carpal tunnel syndrome; Summary of findings 4 Low-level laser
therapy and a splint compared to ultrasound and a splint for carpal
tunnel syndrome; Summary of findings 5 Low-level laser therapy
and a splint compared to placebo and a splint for carpal tunnel
syndrome; Summary of findings 6 Low-level laser therapy, wrist
splint, and vitamin B6 compared to placebo, wrist splint, and
vitamin B6 for carpal tunnel syndrome
Low-level laser therapy versus placebo
Ten randomised trials involving 550 participants (269 randomised
to LLLT) compared LLLT with placebo (Aigner 1999; Chang
2008; Ekim 2007; Evcik 2007; Irvine 2004; Jiang 2011; Lazovic
2014; Shooshtari 2008; Tascioglu 2012; Tikiz 2013).
Study characteristics
Participants
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All 10 trials included people with CTS as diagnosed by the study
authors via clinical findings; five trials also required electrophysio-
logical confirmation on NCS. In trials that reported age, the mean
ranged from 46 to 54 years. The proportion of women where tri-
als provided this demographic information ranged from 77% to
95%. One trial used wrists (including bilateral cases), not partici-
pants, as the unit of analysis and underwent subsequent sensitivity
analysis (Tikiz 2013).
Interventions
The Characteristics of included studies table shows the types of
LLLT used in each trial.
Risk of bias in included studies
We judged Irvine 2004 to be at low risk of bias and all other trials
to be at unclear or high risk of bias. We found no protocols or trial
registry entries for any study included in the review, so our assess-
ment of selective reporting was limited to comparing outcomes
reported in the methods and results sections of publications.
Primary outcomes
Overall improvement in carpal tunnel syndrome: Symptom
Severity Score
An increase in SSS represents increased severity of symptoms. The
scale ranges from 1 to 5, with an MCID of 1.14 (Kim 2013).
Seven trials involving 327 participants (176 randomised to LLLT)
reported SSS in the short term (threemonths or less) (Chang2008;
Ekim 2007; Evcik 2007; Irvine 2004; Jiang 2011; Tascioglu 2012;
Tikiz 2013). Based on the meta-analysis of these seven trials, we
observed no significant difference in SSS of participants treated
with LLLT compared to placebo (MD -0.36, 95% CI -0.78 to
0.06; P = 0.09; Analysis 1.1). The GRADE quality of evidence
was very low. See Summary of findings for the main comparison
for details.
Tikiz 2013 involving 25 participants (13 randomised to LLLT)
reported long-term (12-month) follow-up data for SSS. There was
no significant difference between LLLT and placebo (MD 0.20,
95% CI -0.54 to 0.94; P = 0.6).
Overall improvement in carpal tunnel syndrome: Functional
Status Scale
An increase in FSS represents worsened disability. The scale ranges
from 1 to 5, with an MCID of 0.74 (Kim 2013).
Five trials involving 159 participants (90 randomised to LLLT)
reported FSS (Chang 2008; Ekim 2007; Irvine 2004; Tascioglu
2012; Tikiz 2013). Based on the meta-analysis of these five trials,
we observed a decrease in FSS scores of participants treated with
LLLT compared to placebo (MD -0.56, CI -1.03 to -0.09; P =
0.02; Analysis 1.2). TheGRADE quality of evidence was very low.
Tikiz 2013 involving 25 participants (13 randomised to LLLT)
included long-term (12-month) follow-up data for FSS. There was
no significant difference between LLLT and placebo (MD -0.10,
CI -0.73 to 0.53; P = 0.76).
Secondary outcomes
Visual analogue score pain
An increase inVASpain representsworsenedpain.The scale ranges
from 0 to 10, with an MCID of 1.2 (Kelly 2001).
Seven trials involving 392 participants (209 randomised to LLLT)
reported short-term (threemonths or less) VAS pain (Chang 2008;
Ekim 2007; Evcik 2007; Jiang 2011; Shooshtari 2008; Tascioglu
2012; Tikiz 2013). Based on themeta-analysis of these seven trials,
we observed a significant decrease in VAS pain of participants
treated with LLLT compared to placebo (MD -1.47, 95% CI
-2.36 to -0.58; P = 0.001; Analysis 1.3). The GRADE quality of
evidence was very low.
Lazovic 2014 reported VAS pain following conversion to an or-
dinal outcome: none (0), mild (greater than 0 to 4), moderate
(greater than 4 to 7), and severe (greater than 7 to 10). This study
found a significantly greater reduction in the level of pain following
treatment in the LLLT group compared to the placebo group. A
request was made to authors for original continuous data, however
these were not provided and we were unable to include this trial
in the meta-analysis. Tikiz 2013 included long-term (12-month)
follow-up data for VAS pain. There was no significant difference
between LLLT and placebo (MD -0.22, 95% CI -2.47 to 2.03; P
= 0.85).
Strength measured by dynamometry: grip strength
Five trials involving 286 participants (154 randomised to LLLT)
reported short-term (three months or less) grip strength (Chang
2008; Evcik 2007; Shooshtari 2008; Tascioglu 2012; Tikiz 2013).
Based on the meta-analysis of these five trials, LLLT may increase
grip strength compared to placebo (MD 2.58 kg, 95% CI 1.22
to 3.95; P = 0.0002; Analysis 1.4). The findings did not meet the
MCID for grip strength, which has been reported as 2.69 kg in
healthy people (Villafañe 2014). The GRADE quality of evidence
was low.
Ekim 2007 measured grip strength; however, the paper did not
state the units of measurement or type of dynamometer. There
were no significant differences between LLLT and placebo groups.
We were unable to obtain further information from the study
authors andwewere therefore unable to include data from this trial
in themeta-analysis. Ekim 2007 reported no significant difference
between LLLT and placebo for grip strength. As well as reporting
short-term findings at three months, Tikiz 2013 reported long-
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term (12-month) follow-up data for grip strength. There was no
difference between LLLT and placebo (MD 3.6 kg, 95% CI -2.11
to 9.31; P = 0.22).
Strength measured by dynamometry: finger-pinch strength
Two trials involving 121 participants (61 randomised to LLLT)
reported finger-pinch strength (Chang 2008; Evcik 2007). Based
on the meta-analysis of these two trials, LLLT may increase finger-
pinch strength compared to placebo (MD0.94 kg, 95%CI 0.43 to
1.44; Analysis 1.5). The findings met the MCID for finger-pinch
strength, which has been reported as 0.68 kg in healthy people
(Villafañe 2014). The GRADE quality of evidence was low.
Nerve conduction studies
Seven trials involving 446 participants (236 randomised to LLLT)
reported short-term (three months or less) findings of NCS
(Chang 2008; Ekim 2007; Evcik 2007; Jiang 2011; Lazovic 2014;
Shooshtari 2008; Tascioglu 2012). Tikiz 2013 reported long-term
findings ofNCS for LLLT but not for placebo LLLT.We requested
further information from the study authors however this was not
provided and we were unable to include this trial in the meta-
analysis.
All seven trials reported motor nerve latency. Based on the meta-
analysis of these seven trials, we observed a significant decrease in
the motor nerve latency of participants treated with LLLT com-
pared to placebo (MD-0.09ms, 95%CI -0.16 to -0.03; P = 0.003;
Analysis 1.6). The GRADE quality of evidence was very low.
Five trials involving 307 participants (156 randomised to LLLT)
reported sensory nerve latency (Chang 2008; Ekim 2007; Evcik
2007; Jiang 2011; Shooshtari 2008). Based on themeta-analysis of
these five trials, we observed a significant decrease in sensory nerve
latency of participants treated with LLLT compared to placebo
(MD -0.10 ms, 95% CI -0.15 to -0.06; P < 0.00001; Analysis
1.7). The GRADE quality of evidence was very low.
Two trials involving 139 participants (80 randomised to LLLT)
reported sensory nerve velocity (Lazovic 2014; Tascioglu 2012).
Based on the meta-analysis of these two trials, we observed no sig-
nificant difference in sensory nerve velocity of participants treated
with LLLT compared to placebo (MD 1.48 m/s, 95% CI -5.68
to 8.65; P = 0.68; Analysis 1.8). The GRADE quality of evidence
was very low.
One trial reported sensory and motor amplitude (Evcik 2007).
Evcik 2007 reported no significant difference between pretreat-
ment and post-treatment mean scores for sensory amplitude in the
LLLT group (pretreatment: 28.5 ± 13.4 µV; post-treatment: 29.6
± 12.9 µV) or the placebo group (pretreatment: 27.6 ± 14.7 µV;
post-treatment: 27.9 ± 13.4 µV). Comparing these two groups
following treatment, we found no significant difference (MD 1.7
µV, 95% CI -4.03 to 7.43; P = 0.56). Evcik 2007 also reported
no significant difference between pretreatment and post-treatment
motor amplitude in the LLLT group (pretreatment: 6.8 ± 3.8 mV;
post-treatment: 6.9 ± 3.4 mV) or the placebo group (pretreat-
ment: 7.1 ± 3.3 mV; post-treatment: 7.2 ± 4.0 mV). Comparing
these two groups following treatment, we found no significant dif-
ferences (MD -0.30 mV, 95% CI -1.92 to 1.32; P = 0.72). The
GRADE quality of evidence for all NCS outcomes was very low.
The changes noted in NCS were minimal and did not represent a
clinically important difference (Padua 1997).
Adverse events
This outcome was not reported in any trial.
Any other measure of improvement in symptoms or function
None of the trials reported any other measure of improvement in
symptoms or function.
Variation in statistical analysis
The interpretation of the effect estimate did not change by adopt-
ing the random-effects or fixed-effect model. We chose the ran-
dom-effects model as it is the more conservative of the effect mod-
els. The fixed-effectmodel did not change the direction of effect in
any trial and did not change the direction or size of effect in trials
with low heterogeneity (grip strength, finger-pinch strength).
Jiang 2011 reported change scores, all other trials reported final
mean scores. Jiang 2011 reported two change scores, the initial
change score was used (most significant change). Jiang 2011 re-
ported CTS in two separate groups: mild and moderate, but com-
bined them for analysis. Evcik 2007 and Chang 2008 reported
total SSS and FSS, other trials reported mean SSS and FSS.
Subgroup analysis
We intended to carry out a subgroup analysis comparing trials at
high and low risk of bias but this was not possible because only
one trial was at low risk of bias (Irvine 2004). Irvine 2004 found
no significant difference on any of the outcomemeasures (SSS and
FSS) between LLLT and placebo.
Sensitivity analysis
Tikiz 2013 conducted their study and analysed results in terms of
total number of wrists, not participants. To assess for differences
in the interpretation of the effect estimate that may have occurred
because of this unit-of-analysis error, we performed a sensitivity
analysis utilising multiple different ICCs. These ranged from 0.01
to 1.00. The interpretation of the effect estimate did not change
for any outcome during this analysis.
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Low-level laser therapy versus ultrasound
Three randomised trials involving 177 participants (88 ran-
domised to LLLT) compared LLLT to ultrasound (Bakhtiary
2004; Saeed 2012; Tikiz 2013).
Study characteristics
Participants
All trials included people with CTS as diagnosed by the study
authors via clinical findings and NCS. The mean age in the tri-
als that reported age ranged from 36 to 48 years. The proportion
of females in the trials that provided this demographic informa-
tion ranged from 55% to 88%. In two trials, the unit of analysis
was wrists (including bilateral), not participants, and these trials
underwent subsequent sensitivity analysis (Bakhtiary 2004; Tikiz
2013).
Interventions
The types of LLLT and ultrasound used in the trials are shown in
the Characteristics of included studies table.
Risk of bias in included studies
The risk of bias in the included trials is summarised in the ’Risk
of bias’ summary figure (Figure 2). All studies were at unclear or
high risk of bias. We found no protocols or trial registry entries
for any of the studies included in the review, so our assessment of
selective reporting was limited to comparing outcomes reported
in the methods and results sections of publications.
Primary outcomes
Overall improvement in carpal tunnel syndrome: Symptom
Severity Score
An increase in SSS represents increased severity of symptoms. The
scale ranged from 1 to 5, with an MCID of 1.14.
Two trials involving 127 participants (63 randomised to LLLT)
reported short-term (threemonths or less) SSS. Based on themeta-
analysis of these two trials, SSS was higher (worse) with LLLT
than ultrasound (MD 0.43, 95% CI 0.36 to 0.50; P = 0.00001;
Analysis 2.1). The GRADE quality of evidence was very low. The
findings did notmeet theMCIDof 1.14. See Summary of findings
2 for details.
Tikiz 2013 included long-term (12-month) follow-up data for
SSS. There was no difference between LLLT and ultrasound (MD
0.20, 95% CI -0.55 to 0.95; P = 0.6).
Overall improvement in carpal tunnel syndrome: Functional
Status Scale
An increase in FSS represents worsened disability. The scale ranged
from 1 to 5, with an MCID of 0.74.
Two trials involving 127 participants (63 randomised to LLLT)
reported short-term (three months or less) FSS (Saeed 2012; Tikiz
2013). Based on the meta-analysis of these two trials, FSS was
higher (worse) with LLLT than ultrasound (MD 0.35, 95% CI
0.29 to 0.41; P < 0.0001; Analysis 2.2). The GRADE quality of
evidence was very low. The findings did not meet the MCID of
0.74.
Tikiz 2013 included long-term (12-month) follow-up data for
FSS. There was no significant difference between LLLT and ultra-
sound at 12 months (MD 0.00, 95% CI -0.75 to 0.75; P = 1.00).
Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
Three trials involving 177 participants (88 randomised to LLLT)
reported short-term (three months or less) VAS pain (Bakhtiary
2004; Saeed 2012; Tikiz 2013). Based on the meta-analysis of
these three trials, VAS pain was higher (worse) with LLLT than
ultrasound (MD 2.81, 95% CI 1.21 to 4.40; P < 0.0006; Analysis
2.3). TheGRADEquality of evidence was very low. The difference
met the MCID of 1.2.
Tikiz 2013 included long-term (12-month) follow-up data for
VAS pain. At 12 months, there was no significant difference be-
tween LLLT and ultrasound (MD 1.48, 95% CI -0.56 to 3.52; P
= 0.16).
Strength measured by dynamometry: grip strength
Two trials involving 77 participants (38 randomised to LLLT)
reported grip strength (Bakhtiary 2004; Tikiz 2013). Bakhtiary
2004 reported values in Newtons (converted to kg for meta-anal-
ysis). Based on the meta-analysis of these two trials, we observed
no difference in grip strength of participants treated with LLLT
compared to ultrasound (MD -0.89 kg, 95% CI -4.30 to 2.52; P
= 0.61; Analysis 2.4). The GRADE quality of evidence was very
low.
Tikiz 2013 included long-term (12-month) follow-up data for
grip strength. There was no significant difference between LLLT
and ultrasound (MD 2.70, 95% CI -3.23 to 8.63; P = 0.37).
Strength measured by dynamometry: finger-pinch strength
One trial involving 50 participants (25 randomised to LLLT) re-
ported finger-pinch strength (Bakhtiary 2004). Bakhtiary 2004
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reported a change score for ultrasound as 9.9 ± 5.5 N and LLLT as
2.9 ± 1.5 N. Based on these results, the MD between the change
scores was -7.00 N (95% CI -9.23 to -4.77; P < 0.001). The
GRADE quality of evidence was low.
Nerve conduction studies
Three trials involving 177 participants (88 randomised to LLLT)
reported findings for NCS (Bakhtiary 2004; Saeed 2012; Tikiz
2013). All three trials reported motor nerve latency. Based on the
meta-analysis of these three trials, we observed a significant increase
in motor latency of participants treated with LLLT compared to
ultrasound (MD 0.61 ms, 95% CI 0.27 to 0.95; P = 0.004;
Analysis 2.5). The GRADE quality of evidence was very low.
Tikiz 2013 included long-term (12-month) follow-up data for
motor latency. There was no significant difference between LLLT
and ultrasound (MD 0.10 ms, 95% CI -0.50 to 0.70; P = 0.75).
Three trials involving 177 participants (88 randomised to LLLT)
reported sensory nerve latency (Bakhtiary 2004; Saeed 2012; Tikiz
2013). Based on themeta-analysis of these three trials, we observed
no significant difference in sensory latency of participants treated
with LLLT compared to ultrasound (MD -0.43 ms, 95%CI -0.01
to 0.87; P = 0.05; Analysis 2.6). The GRADE quality of evidence
was very low.
Tikiz 2013 included long-term (12-month) follow-up data for
sensory latency. There was no significant difference between LLLT
and ultrasound (MD -0.20 ms, 95% CI -0.80 to 0.40; P = 0.52).
Two trials involving 77 participants (38 randomised to LLLT)
reported motor amplitude. Based on the meta-analysis of these
two trials, we observed a significant decrease inmotor amplitude of
participants treated with LLLT compared to ultrasound, favouring
ultrasound (MD -1.90 mV, 95% CI -3.63 to -0.18; P = 0.03;
Analysis 2.7). The GRADE quality of evidence was low.
Tikiz 2013 included long-term (12-month) follow-up data for
motor amplitude. There was no significant difference between
LLLT and ultrasound (MD 1.00 mV, 95% CI -2.11 to 4.11; P =
0.53).
Bakhtiary 2004 reported sensory amplitude. The study authors
reported a significant increase in the sensory amplitude of ultra-
sound compared to LLLT (10.1 ± 6.9 µV with ultrasound com-
pared to 4.4 ± 7.4µVwith LLLT). Based on these results, theMD
between the change scores was -5.7 µV (95% CI -9.67 to -1.73;
P = 0.005). The GRADE quality of evidence was very low.
Tikiz 2013 reported sensory velocity. The study authors reported
no significant change for LLLT versus ultrasound at three months
(MD 4.00 m/s, 95% CI -1.49 to 9.49; P = 0.15) or at 12 months
(MD 2.90 m/s, 95% CI -2.02 to 7.82; P = 0.27). The GRADE
quality of evidence was very low.
Adverse events
None of the trials reported this outcome.
Any other measure of improvement in symptoms or function
None of the trials reported any other measure of improvement in
symptoms or function.
Variation in statistical analysis
We used a random-effects model for all outcomes as the more
conservative model. We performed a fixed-effect model analysis
to investigate the small-study effect: where a previous significant
effect had been observed, there was no change in the interpretation
of the effect estimate (VAS pain, motor latency, motor amplitude).
A fixed-effect model produced a change in the effect estimate for
SSS, FSS, grip strength, and sensory latency. Where previously
there had been no significant difference, all produced significant
differences. When a result is statistically significant using a fixed-
effect model but not using a random-effects model, the cause is
likely to be heterogeneity; we chose the random-effects model as
it is the more conservative of the effect models.
Subgroup analysis
We deemed none of the trials at low risk of bias, so we did not
perform a subgroup analysis.
Sensitivity analysis
Bakhtiary 2004 and Tikiz 2013 carried out their study and anal-
ysed their results in terms of total number of wrists, not partici-
pants. We performed a sensitivity analysis to account for a cluster-
ing unit-of-analysis error. The interpretation of the effect estimate
changed for sensory latency to produce a significant difference
with an ICC of 1.00, as a considerably higher weight was given to
Saeed 2012 (see Analysis 2.8 (Figure 3) and Analysis 2.9 (Figure
4)). We chose the most conservative ICC for further discussion
and conclusion; this did not change the interpretation of the effect
estimate. The interpretation of the effect estimate did not change
for any other outcomes during these analyses.
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Figure 3. Sensory latency, pre-analysis.
Figure 4. Sensory latency, intracluster correlation coefficient 1.00.
Low-level laser therapy versus fascial manipulation
One randomised trial involving 42 participants with 70 symp-
tomatic hands (35 wrists randomised to LLLT, number of partic-
ipants randomised to LLLT not stated) compared LLLT to fascial
manipulation (Pratelli 2015).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study au-
thors via clinical findings and NCS. The mean age of participants
was 54 years and 69% were female. This trial analysed its unit of
analysis as wrists (including bilateral), not participants, and un-
derwent subsequent sensitivity analysis.
Interventions
The types of LLLT and fascial manipulation used in the trial are
described in the Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. The risk of bias is summarised
in the ’Risk of bias’ summary figure (Figure 2).
Primary outcomes
Overall improvement in carpal tunnel syndrome: Symptom
Severity Score
An increase in SSS represents increased severity of symptoms. The
scale ranged from 1 to 5, with an MCID of 1.14.
The study authors reported a significant increase in SSS of LLLT
versus fascial manipulation (MD 1.72, 95% CI 1.6 to 1.84). The
GRADE quality of evidence was very low. The findings met the
MCID. See Summary of findings 3 for details.
Overall improvement in carpal tunnel syndrome: Functional
Status Scale
An increase in FSS represents worsened disability. The scale ranged
from 1 to 5, with an MCID of 0.74.
The study authors reported a significant increase in FSS of LLLT
versus fascial manipulation (MD 1.31, 95%CI 1.02 to 1.60). The
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GRADE quality of evidence was very low. The findings met the
MCID. See Summary of findings 3 for details.
Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
The study authors reported a significant increase in VAS pain of
LLLT versus fascial manipulation (MD 4.32, 95% CI 3.67 to
4.97). TheGRADE quality of evidence was very low. The findings
met the MCID.
Unreported outcomes
Study authors did not measure or report on the following out-
comes: strength measured by dynamometry (grip strength and fin-
ger-pinch strength), NCS, adverse events, and any other measure
of improvement in symptoms or function.
Sensitivity analysis
The unit of analysis was wrists, not participants. We performed
a sensitivity analysis to account for a clustering unit-of-analysis
error. The interpretation of the effect estimate did not change for
any outcome during this analysis.
Low-level laser therapy versus pulsed magnetic field
One randomised trial involving 38 participants (18 randomised
to LLLT) compared LLLT to PMF (Dakowicz 2011).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study au-
thors via clinical findings and NCS. The mean age of participants
was 51 years and 92% were female.
Interventions
The types of LLLT and PMF used in the trial are described in the
Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. The risk of bias is summarised
in the ’Risk of bias’ summary figure (Figure 2).
Secondary outcomes
Visual analogue score pain
The study authors reportedmeanVAS pain values in a graph. They
reported a significant reduction from baseline in both groups but
did not report the significance of any difference when comparing
the two groups. They did not report the measure of spread (e.g.
standard deviation) and so we were unable to perform further
analysis.We requested further information but nonewas provided.
Nerve conduction studies
The study authors reported that changes in sensory and motor
latency were not significant, but did not present values.
Unreported outcomes
The study authors did not measure or report on the following out-
comes: overall improvement in carpal tunnel syndrome: SSS, over-
all improvement in carpal tunnel syndrome: FSS, strength mea-
sured by dynamometry (grip strength and finger-pinch strength),
adverse events, and any other measure of improvement in symp-
toms or function.
Low-level laser therapy versus transcutaneous
electrical nerve stimulation
One randomised trial involving 20 participants (10 randomised
to LLLT) compared LLLT to TENS (Casale 2013).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study
authors via clinical findings and NCS. The mean age in the trial
was 54 years and 69% of the participants were female.
Interventions
The types of LLLT and TENS used in the trial are described in
the Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. This is summarised in the ’Risk
of bias’ summary figure (Figure 2).
We did not produce a ’Summary of findings’ table for this com-
parisons as no data for any prespecified outcomes were available.
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Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
Analysis of the study authors’ findings revealed a significant de-
crease in VAS pain of participants treated with LLLT compared to
TENS (MD -1.20, 95% CI -2.27 to -0.13). The GRADE quality
of evidence was very low.
Nerve conduction studies
Analysis of the authors’ findings revealed a decrease in the motor
latency of participants treated with LLLT compared to TENS
(MD -0.70 ms, 95% CI -1.17 to -0.23) and an increase in the
sensory nerve conduction velocity (MD 3.9 m/s, 95% CI 0.27 to
7.53). The GRADE quality of evidence for both outcomes was
very low.
Unreported outcomes
The study authors did not measure or report on the following out-
comes: overall improvement in carpal tunnel syndrome: SSS, over-
all improvement in carpal tunnel syndrome: FSS, strength mea-
sured by dynamometry (grip strength and finger-pinch strength),
adverse events, and any other measure of improvement in symp-
toms or function.
Low-level laser therapy versus steroid injection
Two randomised trials involving 73 participants (36 randomised
to LLLT) compared LLLT to steroid injection (Lucantoni 1992;
Soltani 2013).
Study characteristics
Participants
Both trials included people with CTS as diagnosed by the study
authors via clinical findings and NCS. The mean age in Lucantoni
1992 was not stated. The mean age in Soltani 2013 was 47 years.
Across both trials, 93% of participants were female. Both trials
analysed their unit of analysis as wrists (including bilateral), not
participants, and underwent subsequent sensitivity analysis.
Interventions
The types of LLLT and steroid injection used in the trials are
described in the Characteristics of included studies table.
Risk of bias in included studies
Both trials were at high risk of bias. This is summarised in the
’Risk of bias’ summary figure (Figure 2).
We did not produce a ’Summary of findings’ table for this compar-
ison as there were no data for any prespecified outcome available.
Secondary outcomes
Visual analogue score pain
Analysis of the findings of Soltani 2013 revealed no significant
difference inVASpain of participants treatedwith LLLTcompared
to steroid injection (MD -0.50, 95% CI -1.80 to 0.80; P = 0.45).
Nerve conduction studies
Analysis of the findings of Lucantoni 1992 revealed no significant
short-term difference in motor latency of participants treated with
LLLT compared to steroid injection (MD -0.09 ms, 95%CI -0.58
to 0.40) or sensory nerve conduction velocity (MD -1.14 m/s,
95% CI -4.34 to 2.06). The GRADE quality of evidence of both
outcomes was very low. Analysis of the study authors’ findings
revealed no significant long-term difference in motor latency of
participants treatedwith LLLT compared to steroid injection (MD
-0.48 ms, 95% CI -1.06 to 0.10) or sensory nerve conduction
velocity (MD -0.75 m/s, 95% CI -4.31 to 2.81). The GRADE
quality of evidence of both outcomes was very low.
Analysis of the findings of Soltani 2013 revealed no significant dif-
ference in motor latency of participants treated with LLLT com-
pared to steroid injection (MD 0.00 ms, 95% CI -0.48 to 0.48)
or sensory latency (MD -0.20 ms, 95% CI -0.51 to 0.11). The
study authors reported no significant changes for sensory or motor
amplitude but did not report the findings.
Both trials reportedmotor latency. Based onmeta-analysis of these
two trials, we observed no significant difference in motor latency
of participants treated with LLLT compared to steroid injection
(MD -0.04 ms, 95% CI -0.39 to 0.30; P = 0.80) (Analysis 3.1).
The GRADE quality of evidence was very low.
Soltani 2013 also reported short-term outcomes for sensory la-
tency, sensory amplitude, and motor amplitude. Analysis of their
findings revealed no significant difference of participants treated
with LLLT compared to steroid injection in sensory amplitude
(MD -3.60 µV, 95% CI -7.34 to 0.14; P = 0.06), sensory latency
(MD -0.10 ms, 95% CI -0.34 to 0.14; P = 0.42), or motor am-
plitude (MD -0.20 mV, 95% CI -0.61 to 0.21; P = 0.34). The
GRADE quality of evidence of these outcomes was very low.
Any other measure of improvement in symptoms or
function: symptom improvement questionnaires
Lucantoni 1992 reported a symptom improvement questionnaire:
no improvement, slight improvement, moderate improvement,
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disappearance of symptoms. We converted this to a 1 (disappear-
ance) to 4 (no improvement) scale for analysis as a discontinuous
ordinal outcome. Analysis of the findings of Lucantoni 1992 re-
vealed less of an improvement in the short-term symptoms of par-
ticipants treated with LLLT compared to steroid injection (MD
0.95, 95% CI 0.29 to 1.61; P = 0.005). The GRADE quality of
evidence was very low.
Analysis of the findings of Lucantoni 1992 revealed no difference
in the long-term (six months) symptoms of participants treated
with LLLT compared to steroid injection (MD 0.20, 95% CI
-0.46 to 0.86; P = 0.55). The GRADE quality of evidence was
very low.
Unreported outcomes
The study authors did not measure or report on the following out-
comes: overall improvement in carpal tunnel syndrome: SSS, over-
all improvement in carpal tunnel syndrome: FSS, strength mea-
sured by dynamometry (grip strength and finger-pinch strength),
and adverse events.
Sensitivity analysis
The unit of analysis was not specified by the study authors in ei-
ther of the trials. However, both contained participants who were
treated for bilateral symptoms. To assess for units-of-analysis er-
ror, we performed a sensitivity analysis utilising multiple different
ICCs to assess for differences in interpretation of effect estimate.
The ICCs ranged from 0.01 to 1.00. The interpretation of the
effect estimate did not change for any outcome during these anal-
yses.
Low-level laser therapy versus wrist splint and non-
steroidal anti-inflammatory drugs
One randomised trial involving 42 participants (21 randomised
to LLLT) compared LLLT to wrist splint and NSAIDs (Rodrigues
2013).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study
authors via clinical findings and NCS. The mean age in the trial
was 50 to 59 years and 95% of the participants were female.
Interventions
The types of LLLT and wrist splint with NSAIDs used in the trial
are described in the Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. This is summarised in the ’Risk
of bias’ summary figure (Figure 2).
We did not produce a ’Summary of findings’ table for this com-
parisons as no data for any prespecified outcomes were available.
The reported outcomes were assessed at short term (less than three
months) follow-up. The authors did not investigate long-term
outcomes.
Secondary outcomes
Nerve conduction studies
The study authors categorised the NCS findings into mild, mod-
erate, and severe. We converted them to continuous outcomes (1,
2, and 3, respectively). Analysis of the study authors’ findings re-
vealed no significant difference in the improvement in NCS of
people treated with LLLT compared to wrist splint and NSAIDs
(MD -0.48, 95% CI -0.98 to 0.02; P = 0.06). The GRADE qual-
ity of evidence was very low.
Any other measure of improvement in symptoms or
function: symptom improvement questionnaires
The study authors categorised symptoms as: without pain, light
pain, moderate pain, and severe pain. In the LLLT group, the per-
centage in each of these categories were, respectively, 9.6%, 19%,
52.4%, and 19% before treatment versus 66.6%, 23.8%, 9.6%,
and 0% after treatment. Corresponding data for the wrist splint
and NSAID group were 0%, 4.8%, 61.8% and 33.4% before
treatment versus 4.8%, 57.2%, 38%, and 0% after treatment.
Unreported outcomes
The study authors did not measure or report on the following
outcomes: overall improvement in carpal tunnel syndrome: SSS,
overall improvement in carpal tunnel syndrome: FSS, VAS pain,
strength measured by dynamometry (grip strength and finger-
pinch strength), and adverse events.
Low-level laser therapy versus tendon gliding
exercises
One randomised trial involving 30 participants (15 randomised
to LLLT) compared LLLT to TGEs (Atya 2011).
Study characteristics
Participants
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The trial included people with CTS as diagnosed by the trial au-
thors via clinical findings and NCS. All participants were female,
and the mean age was 38 years.
Interventions
The types of LLLT and TGE used in the trial are described in the
Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. This is summarised in the ’Risk
of bias’ summary figure (Figure 2).
Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
The study authors reported a decrease in VAS pain of people
treated with LLLT compared to TGE (MD -2.34, 95% CI -3.35
to -1.33; P < 0.001).
Strength measured by dynamometry: grip strength
The study authors reported an increase in the grip strength of
people treated with LLLT compared to TGE (MD 4.6 kg, 95%
CI 2.73 to 6.47; P < 0.001). The GRADE quality of evidence was
very low.
Nerve conduction studies
The study authors reported a significant difference in NCS of
people treated with LLLT compared to TGE, favouring LLLT for
motor latency (MD -0.82 ms, 95% CI -1.18 to -0.46; P < 0.001),
sensory latency (MD -0.33ms, 95%CI -0.54 to -0.12; P = 0.002),
and sensory conduction velocity (MD 1.74 m/s, 95% CI 0.60
to 2.88; P = 0.003). The GRADE quality of evidence of these
outcomes was very low.
Unreported outcomes
The study authors did not measure or report on the following out-
comes: overall improvement in carpal tunnel syndrome: SSS, over-
all improvement in carpal tunnel syndrome: FSS, strength mea-
sured by dynamometry (finger-pinch strength), adverse events,
and any other measure of improvement in symptoms or function.
Low-level laser therapy (as part of multiple
interventions) versus other non-surgical interventions
Low-level laser therapy and wrist splint versus
ultrasound and wrist splint
One randomised trial involving 60 participants with 120 symp-
tomatic wrists (100 wrists completed, 36 wrists randomised to
LLLT, number of participants randomised to LLLT not stated)
compared LLLT and splint to ultrasound and wrist splint (Dincer
2009).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study
authors via NCS. The mean age of participants was 46 years and
100% were female. This trial analysed its unit of analysis as wrists
(including bilateral), not participants, and underwent subsequent
sensitivity analysis.
Interventions
The types of LLLT, wrist splint, and ultrasound used in the trial
are described in the Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. The risk of bias is summarised
in the ’Risk of bias’ summary figure (Figure 2).
Primary outcomes
Overall improvement: Symptom Severity Score
An increase in SSS represents increased severity of symptoms. The
scale ranged from 1 to 5, with an MCID of 1.14.
The study authors reported a significant decrease in SSS of LLLT
and wrist splint versus ultrasound and wrist splint (MD -0.71,
95% CI -1.06 to -0.36; P = 0.0003). The GRADE quality of
evidence was very low. The findings did not meet the MCID. See
Summary of findings 4 for details.
Overall improvement: Functional Status Scale
An increase in FSS represents worsened disability. The scale ranged
from 1 to 5, with an MCID of 0.74.
The study authors reported no significant differences in FSS of
LLLT and wrist splint versus ultrasound and wrist splint (MD
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-0.18, 95% CI -0.46 to 0.10; P = 0.18). The GRADE quality of
evidence was very low. The findings did not meet the MCID.
Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
The study authors reported a significant decrease in VAS pain of
LLLT and wrist splint versus ultrasound and wrist splint (MD
-1.25, 95% CI -2.28 to -0.22; P = 0.008). The GRADE quality
of evidence was very low. The findings did not meet the MCID.
Nerve conduction studies
The study authors reported numerical values for sensory velocity
and motor distal latency only. They reported no significant differ-
ence between LLLT and wrist splint versus ultrasound and wrist
splint in sensory velocity (MD 2.67 m/s, 95% CI -1.04 to 6.38; P
= 0.11) or motor latency (MD -0.07 ms, 95% CI -0.21 to 0.07; P
= 0.36). The GRADE quality of evidence for both outcomes was
very low.
Unreported outcomes
The study authors did not measure or report on the following
outcomes: strength measured by dynamometry (grip strength and
finger-pinch strength), adverse events and any other measure of
improvement in symptoms or function.
Sensitivity analysis
The unit of analysis used was wrists, not participants. We per-
formed a sensitivity analysis to account for a clustering unit-of-
analysis error. The interpretation of the effect estimate did not
change for any outcome during this analysis.
Low-level laser therapy and wrist splint versus
placebo LLLT and wrist splint
One randomised trial involving 66 participants with 112 symp-
tomatic wrists (112 wrists completed, 56 wrists randomised to
LLLT, number of participants randomised to LLLT not stated)
compared LLLT and wrist splint to placebo LLLT and wrist splint
(Fusakul 2014).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study
authors via NCS. The mean age of participants was 51 years and
96% were female. This trial analysed its unit of analysis as wrists
(including bilateral), not participants, and underwent subsequent
sensitivity analysis.
Interventions
The types of LLLT and splint used in the trial are described in the
Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. The risk of bias is summarised
in the ’Risk of bias’ summary figure (Figure 2).
Primary outcomes
Overall improvement: Symptom Severity Score
An increase in SSS represents increased severity of symptoms. The
scale ranged from 1 to 5, with an MCID of 1.14.
The study authors reported no significant differences in SSS of
LLLT and wrist splint versus placebo LLLT and wrist splint (MD
0.14, 95% CI -0.06 to 0.34; P = 0.17). The GRADE quality of
evidence was very low. The findings did not meet the MCID. See
Summary of findings 5 for details.
Overall improvement: Functional Status Scale
An increase in FSS represents worsened disability. The scale ranged
from 1 to 5, with an MCID of 0.74.
The study authors reported no significant differences in FSS of
LLLT and wrist splint versus placebo LLLT and wrist splint (MD
0.16, 95% CI -0.04 to 0.36; P = 0.11). The GRADE quality of
evidence was very low. The findings did not meet the MCID.
Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
The study authors reported a significant increase in VAS pain of
LLLT and wrist splint versus placebo LLLT and wrist splint (MD
0.97, 95% CI 0.83 to 1.11; P < 0.00001). The GRADE quality
of evidence was very low. The findings did not meet the MCID.
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Strength measured by dynamometry: grip strength
The study authors reported a significant increase in grip strength
of LLLT and wrist splint versus placebo LLLT and wrist splint
(MD 0.89 kg, 95% CI 0.49 to 1.29; P < 0.00001). The GRADE
quality of evidence was very low. The findings did not meet the
MCID.
Strength measured by dynamometry: finger-pinch strength
The study authors reported no significant differences in finger-
pinch strength of LLLT and wrist splint versus placebo LLLT and
wrist splint (MD -0.07 kg, 95% CI -0.18 to 0.04; P = 0.21). The
GRADE quality of evidence was very low. The findings did not
meet the MCID.
Nerve conduction studies
The study authors reported a significant decrease in sensory latency
(MD -0.18 ms, 95% CI -0.24 to -0.12; P < 0.00001) and motor
latency (MD -1.90 ms, 95% CI -2.19 to -1.61; P < 0.00001) with
a significant increase in sensory amplitude (MD 1.09 µV, 95%
CI 0.44 to 1.74; P = 0.001) and no significant changes for motor
amplitude (MD 0.01 mV, 95% CI -0.12 to 0.14; P = 0.88) of
LLLT and wrist splint versus placebo LLLT and wrist splint. The
changes noted in NCS did not represent a clinically important
difference (Padua 1997).
Adverse events
The study authors reported that two participants experienced pain
of a mild degree in both hands: one received laser therapy and the
other received placebo laser. A further two participants had ex-
perienced discomfort of tingling sensation during laser treatment
only in the hand which received laser therapy but not in the other
hand which received placebo laser. Based on this, we observed no
significant difference in adverse events between LLLT and a wrist
splint versus placebo LLLT and a wrist splint (RR 2.00, 95% CI
0.38 to 10.48; P = 0.41).
Unreported outcomes
The study authors did not measure or report on the following out-
come: any other measure of improvement in symptoms or func-
tion.
Sensitivity analysis
The unit of analysis used was wrists, not participants. We per-
formed a sensitivity analysis to account for a clustering unit-of-
analysis error. The interpretation of the effect estimate did not
change for any outcome during this analysis.
Low-level laser therapy, a wrist splint, and vitamin B6
versus placebo low-level laser therapy, a wrist splint,
and vitamin B6
One randomised trial involving 50 participants (18 randomised to
LLLT) compared LLLT, a wrist splint, and vitamin B6 to placebo
LLLT, a wrist splint, and vitamin B6 (Rayegani 2013).
Study characteristics
Participants
The trial included people with CTS as diagnosed by the study au-
thors via clinical findings and NCS. The mean age of participants
was 49 years. Information on gender was not available.
Interventions
The types of LLLT and splint used in the trial are described in the
Characteristics of included studies table.
Risk of bias in included studies
The trial was at high risk of bias. The risk of bias is summarised
in the ’Risk of bias’ summary figure (Figure 2).
Primary outcomes
Overall improvement: Symptom Severity Score
The study authors reported using, and referenced, SSS but they
provided results outside the normal range (1 to 5). As such, the
range orMCIDwas unknown. Further information regarding this
was not available in the text. From our analysis, we observed a sig-
nificant increase in SSS of the LLLT group versus placebo group
(MD 3.50, 95% CI 0.29 to 6.71; P = 0.03). The GRADE qual-
ity of evidence was very low. However, the study authors stated
that there were no significant differences in improved disability
between groups. Further information was not provided. We con-
tacted trial authors for further information; however, this was not
provided. See Summary of findings 6 for details.
Overall improvement: Functional Status Scale
The study authors reported to using, and referencing, FSS but
they provided results outside the normal range (1 to 5). As such,
the range or MCID was unknown. The study authors reported no
significant differences in FSS of the LLLT group versus placebo
LLLT group (MD -0.70, 95% CI -2.76 to 1.36; P = 0.45). The
GRADEquality of evidencewas very low. See Summary of findings
6 for details.
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Secondary outcomes
Visual analogue score pain
An increase in VAS pain represents worsened pain. The scale
ranged from 0 to 10, with an MCID of 1.2.
The study authors reported no significant difference in VAS pain
of the LLLT group versus placebo LLLT group (MD 0.90, 95%
CI -1.03 to 2.83; P = 0.08). The GRADE quality of evidence was
very low.
Nerve conduction studies
The study authors reported no significant difference in sensory
latency (MD 0.20 ms, 95% CI -0.33 to 0.73; P = 0.46), motor
latency (MD 0.30 ms, 95% CI -0.16 to 0.76; P = 0.20), sensory
amplitude (MD -2.00 µV, 95% CI -13.05 to 9.05; P = 0.72),
or motor amplitude (MD -0.40 mV, 95% CI -2.46 to 1.66; P =
0.70) of the LLLTgroup versus placebo LLLTgroup.TheGRADE
quality of evidence for all outcomes was very low.
Unreported outcomes
The study authors did not measure or report on the following
outcomes: strength measured by dynamometry (grip strength and
finger-pinch strength), adverse events, and any other measure of
improvement in symptoms or function.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Low- level laser therapy compared to ultrasound for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy
Comparison: ultrasound
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with ultrasound Risk with low- level
laser therapy
Overall improvement in
CTS: SSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
1.8
MD 0.43 higher
(0.36 higher to 0.5
higher)
- 127
(2 RCTs)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: SSS: long term
Scale f rom: 1 to 5
Follow-up: mean 12
months
The mean overall im-
provement (as mea-
sured by SSS) long term
was 2
MD 0.2 higher
(0.55 lower to 0.95
higher)
- 27
(1 RCT)
⊕©©©
Very low 1,3,4,5
-
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean FSS short
term (< 3 months) was
1.9
MD 0.35 higher
(0.29 higher to 0.41
higher)
- 127
(2 RCTs)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term
Scale f rom: 1 to 5
Follow-up: mean 12
months
The mean FSS long
term was 2.2
MD 0
(0.075 lower to 0.75
higher)
- 27
(1 RCT)
⊕©©©
Very low 1,3,4,5
-
2
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Adverse events - - - - - No adverse events re-
ported in any trial.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: mean dif ference; RCT: randomised controlled trial; SSS: Symptom Severity Score.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Lit t le overlap of conf idence intervals and heterogeneity in magnitude of ef fect.
3 Total sample size under 400 in total in both groups.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
5 Only one trial.
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Low- level laser therapy compared to fascial manipulation for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy
Comparison: f ascial manipulat ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with fascial ma-
nipulation
Risk with low- level
laser therapy
Overall improvement in
CTS: SSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
1.28
MD 1.72 higher
(1.6 higher to 1.84
higher)
- 70
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS:SSS: long term -
not reported
- - - - - -
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean FSS short
term (< 3 months) was
1.32
MD 1.31 higher
(1.02 higher to 1.6
higher)
- 70
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term
- - - - - Not reported.
Adverse events - - - - - Not reported.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: mean dif ference; RCT: randomised controlled trial; SSS: Symptom Severity Score.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Total sample size under 400 in both groups.
3 Only one trial.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
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Low- level laser therapy and a splint compared to ultrasound and a splint for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy + splint
Comparison: ultrasound + splint
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with ultrasound
and a splint
Risk with low- level
laser therapy and a
splint
Overall improvement in
CTS:SSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
-0.95
MD 0.71 lower
(1.06 lower to 0.36
lower)
- 66
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS:SSS: long term -
not measured
- - - - - -
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean FSS short
term (< 3 months) was
-0.80
MD 0.18 lower
(0.46 lower to 0.10
higher)
- 66
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term -
not reported
- - - - - -
Adverse events - - - - - Not reported.
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: mean dif ference; RCT: randomised controlled trial; SSS: Symptom Severity Score.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Total sample size under 400 in total in both groups.
3 Only one trial.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
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Low- level laser therapy and a splint compared to placebo and a splint for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy and a splint
Comparison: placebo and a splint
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo and
a splint
Risk with low- level
laser therapy and a
splint
Overall improvement in
CTS: SSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
1.35
MD 0.14 higher
(0.06 lower to 0.34
higher)
- 112
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: SSS: long term -
not measured
- - - - - -
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale f rom: 1 to 5
The mean FSS short
term (< 3 months) was
1.37
MD 0.16 higher
(0.04 lower to 0.36
higher)
- 112
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term -
not measured
- - - - - -
Adverse events Study populat ion RR 2.00
(0.38 to 10.48)
112
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
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36 per 1000 71 per 1000
(14 to 374)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SSS: Symptom
Severity Score.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Total sample size under 400 in total in both groups.
3 Only one trial.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
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Low- level laser therapy, wrist splint, and vitamin B6 compared to placebo, wrist splint, and vitamin B6 for carpal tunnel syndrome
Patient or population: carpal tunnel syndrome
Setting:
Intervention: low-level laser therapy, wrist splint , and vitamin B6
Comparison: placebo, wrist splint , and vitamin B6
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo +
wrist splint + vitamin
B6
Risk with low- level
laser therapy + wrist
splint + vitamin B6
Overall improvement in
CTS: SSS: short term (<
3 months)
Scale unknown
The mean overall im-
provement (as mea-
sured by SSS) short
term (< 3 months) was
3
MD 3.50 higher
(0.29 higher to 6.71
higher)
- 33
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: SSS: long term -
not measured
- - - - - -
Overall improvement in
CTS: FSS: short term (<
3 months)
Scale not known
The mean FSS short
term (< 3 months) was
4.4
MD 0.7 lower
(2.76 lower to 1.36
higher)
- 33
(1 RCT)
⊕©©©
Very low 1,2,3,4
-
Overall improvement in
CTS: FSS: long term -
not reported
- - - - - -
Adverse events - - - - - Not reported.
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CTS: carpel tunnel syndrome; FSS: Funct ional Status Scale; MD: mean dif ference; RCT: randomised controlled trial; SSS: Symptom Severity Score.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 High risk of bias.
2 Total sample size under 400 in total in both groups.
3 Only one trial.
4 Because of the few trials, we were unable to assess publicat ion bias by funnel plot.
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D I S C U S S I O N
Summary of main results
This systematic review and meta-analysis aimed to determine the
effectiveness and associated risk of LLLT compared with placebo
or other non-surgical treatments for improving clinical and elec-
trophysiological outcomes in people with CTS. The review in-
cluded 22 trials randomising 1153 participants; nine studies com-
pared LLLT with placebo, two studies compared LLLT with ultra-
sound, one study compared LLLT with placebo and LLLT with
ultrasound, two studies compared LLLT with steroid injection,
and one each compared LLLT with other non-surgical interven-
tions: fascial manipulation, PMF, TENS, TGEs, and wrist splint
with NSAIDs. Three trials compared LLLT as part of multiple in-
terventions: one compared LLLT and applying a wrist splint with
ultrasound and applying a wrist splint; one compared LLLT and
applying a wrist splint with placebo and applying a wrist splint;
and one compared LLLT, applying a wrist splint, and vitamin B6
with placebo LLLT, applying a wrist splint, and vitamin B6.
Irvine 2004 was at low risk of bias. All other included studies were
at high or unclear overall risk of bias. Many were not blinded. The
quality of the studies across outcomes for each intervention was
largely very low, and any point estimates of effect or harm should
be interpreted with great caution. Evenwithout this fact, the effect
sizes seen were modest or small and may not have any clinical
relevance. Overall, there is insufficient evidence to establish any
effect of LLLT over placebo or other non-surgical interventions
for CTS. Limited and very low quality evidence exists for the
effects of LLLT in the treatment of CTS and we found no data to
support any clinically useful effect of LLLT in treating CTS. There
is very low-quality evidence that LLLT may result in a greater
improvement in VAS pain, motor nerve latency, and sensory nerve
latency, and low-quality evidence that LLLTmay result in a greater
improvement in grip and finger-pinch strength, when compared
with placebo at short-term (under three months) follow-up but
the magnitude of any effect, although statistically significant, is of
little benefit clinically.
The changes noted in NCSs are minimal and do not represent
clinically important differences (Padua 1997). We could not de-
fine the MCID for grip and finger-pinch strength for people with
CTS from any literature. They have been reported in healthy peo-
ple, however, as 2.69 kg for grip strength and 0.68 kg for finger-
pinch strength (Villafañe 2014). Based on this, we interpreted our
findings as a clinically insignificant change for grip strength (2.58
kg) and in meeting the MCID for pinch-strength (0.94 kg).
There is very low-quality evidence that LLLT may result in a lesser
improvement in VAS pain and motor nerve latency and low-qual-
ity evidence that LLLT may result in a lesser improvement in fin-
ger-pinch strength and motor nerve amplitude when compared
with ultrasound at short-term follow-up. These results are also as
sensitive to bias as those indicating improvement in the opposite
direction.
One trial examining long-term (12-month) follow-up found no
significant improvements in VAS pain, SSS, FSS, grip strength, or
NCS for LLLT compared to placebo or ultrasound.
For short-term outcomes from other non-surgical interventions,
LLLT versus fascial manipulation favoured fascial manipulation
for SSS, FSS, and VAS pain. LLLT versus PMF found no sig-
nificant differences in VAS pain or NCS. LLLT versus TENS
favoured LLLT for VAS pain and NCS (motor latency, sensory
nerve conduction velocity). LLLT versus steroid injection revealed
a significant difference in symptom improvement questionnaires
favouring steroid injection, but there were significant differences
for VAS pain or NCS. Lucantoni 1992 also examined long-term
follow-up, for which there was no significant difference between
LLLT and steroid injection. LLLT versus TGEs favoured LLLT
for VAS pain, grip strength, and NCS (motor latency, sensory la-
tency, and sensory conduction velocity). LLLT versus wrist splint
and NSAIDs favoured LLLT for symptom improvement ques-
tionnaires but there was no significant difference with NCS. LLLT
versus TENS was at unclear risk of bias; all other non-surgical
intervention trials were at high risk of bias and their results should
be interpreted with great caution. A series of small studies of this
type will usually overestimate the beneficial effects.
Only one study, Fusakul 2014, reported adverse events. They re-
ported adverse events in four wrists (8%) consisting of mild wrist
pain in two and discomfort during treatment in two. After the end
of laser treatment, these symptoms resolved.
Overall completeness and applicability of
evidence
For assessment of risk of bias, several of the included studies did
not report information on important factors regarding study con-
duct. These included details about the method of random se-
quence generation, allocation concealment, method of blinding,
methods used to handle missing data, and handling of bilateral
wrist data to avoid unit-of-analysis error, all of which result in
bias. For example, the authors of 12 studies did not report suffi-
cient information to determine if they used an adequate method
of allocation concealment. This is an important aspect of study
conduct which meta-analysis of epidemiological evidence suggests
can result in biased treatment effects (Savovi 2012).
The mean age ranged from 46 to 54 years in LLLT versus placebo
trials and 36 to 48 years in LLLT versus ultrasound trials. The
results of this meta-analysis apply to populations with a similar
age demographic.
Only one study, Tascioglu 2012, compared different regimens of
LLLT and no studies provided a comparative assessment of LLLT
delivered over different time scales (e.g. three weeks of LLLT treat-
ment compared to three months). Therefore, there is insufficient
evidence regarding the optimum duration of LLLT treatment.
Only one study, Fusakul 2014, reported on adverse events. Other
studies did not specify within the results if no adverse events oc-
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curred and so conclusions regarding adverse events cannot bemade
as the evidence is lacking.
The included studies were limited in the duration of follow-up
for outcome assessment. Only one study assessed the long-term
effects of LLLT versus placebo or LLLT versus therapeutic ul-
trasound, and one assessed the long-term effects of LLLT versus
steroid injection. These trials showed no significant difference be-
tween LLLT and the comparison intervention across all outcomes
(Lucantoni 1992; Tikiz 2013). No other studies assessed the long-
term outcomes of LLLT versus any other comparator. We cannot,
therefore, draw conclusions regarding the long-term outcomes of
LLLT versus the comparators listed within this review.
Quality of the evidence
Risk of bias varied across the studies, but was generally high in
most domains. All studies were small, ranging from 15 to 100
participants and therefore an overestimation of any effect is likely.
Lack of participant blinding may have influenced the self-reported
outcomes of VAS pain, SSS, and FSS.
There was inconsistency throughout all comparisons. Within the
LLLT versus placebo comparison, all outcomes presented signifi-
cant inconsistency. There was substantial and considerable hetero-
geneity across several outcomes: VAS pain (I² = 92%), SSS (I² =
98%), and FSS (I² = 89%). These outcomes also had little overlap
of CIs, and heterogeneity in magnitude of effect. Grip and fin-
ger-pinch strength had no inconsistency across trials, both with
a calculated I² statistic of 0% and CIs consistently overlapping.
Although motor nerve latency and sensory nerve latency had an I²
statistic of 0%, they had little overlap of CIs and heterogeneity in
the direction of effect; therefore, we downgraded the quality of ev-
idence.Within the LLLT versus ultrasound comparison, we noted
substantial heterogeneity for VAS pain (I² = 89%) and moderate
heterogeneity for motor amplitude (I² = 39%), with little over-
lap of CIs and heterogeneity in magnitude of effect for both out-
comes. SSS and FSS had no heterogeneity, with good overlap of
CIs and I² = 0%. There was little overlap of CIs and heterogeneity
in the direction of effect across the outcomes grip strength (I² =
42%), motor latency (I² = 83%), and sensory latency (I² = 65%).
Assessment of inconsistency was not possible in other outcomes
or comparisons.
In the comparison LLLT versus placebo, motor latency had no
imprecision, with a sample size greater than 400 in total in both
groups and the CIs not including the MCID on either side of
zero. We downgraded the quality of evidence for imprecision for
all other outcomes in LLLT versus placebo and downgraded the
quality of evidence for imprecision across all other comparisons
due to the total study sample size being less than 400.
We intended to draw funnel plots to distinguish between publi-
cation bias and other causes of asymmetry. However, there were
insufficient studies to conduct these analyses. Caution should be
taken in the interpretation of the results in light of possible pub-
lication bias.
Potential biases in the review process
Wemade all efforts to minimise bias in this systematic review and
meta-analysis process. We conducted this systematic review and
meta-analysis in accordance with the PRISMA reporting guide-
lines for the conduct of meta-analysis of interventional trials. We
published a trial protocol prior to commencement of the system-
atic review (Other published versions of this review). We searched
four electronic databases using search strategies suitable for iden-
tification of RCTs. There were no limitations to the search with
regards to language or publication status. We handsearched refer-
ence lists of studies for further references and we searched clini-
cal trial registries for ongoing studies. Two review authors inde-
pendently carried out selection of studies, data extraction, and
’Risk of bias’ with disagreements resolved through a third inde-
pendent review author. This decreased the risk of bias within the
review process. Further databases that could have been searched
to identify additional trials include the Cochrane Neuromuscular
Specialised Register and allied health databases such as Allied and
Complementary Medicine Database (AMED), Cumulative Index
to Nursing and Allied Health Literature (CINAHL), or Physio-
therapy Evidence Database (PEDro).
Limitations include difficulty obtaining relevant unpublished data
from authors of included studies. We could not find protocols
or trial registry entries for the included studies, which restricted
our ability to assess selective outcome reporting. Only one trial
reported adverse events and all studies were small in participant
numbers. With this regard, rare adverse events were unlikely to
have been detected from trial data. The review was initially un-
dertaken as a thesis with Cochrane Neuromuscular and subse-
quently adapted to comply with Cochrane publishing guidelines.
CochraneNeuromuscular states preferencewithin published guid-
ance for one primary outcome and up to five secondary out-
come measures. As such, we changed primary and secondary out-
comes from the original protocol to comply with this. SSS and
FSS remained as the primary outcome measure (overall improve-
ment) while we changed the remaining primary outcomes to sec-
ondary outcomes. Secondary outcomes were grouped where possi-
ble (while previously grip strength and finger-pinch strength were
separate outcomes, they are now paired as dynamometry). All out-
comes from the initial protocol were included within the text and
reported separately however to reduce selective reporting bias. No
other changes were made to the protocol. In the initial thesis, all
outcomes were listed for inclusion within the ’Summary of find-
ings’ tables. The selection of outcomes for inclusion in the ’Sum-
mary of findings’ tables in this review is therefore retrospective and
a potential bias in the review process.
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Agreements and disagreements with other
studies or reviews
We found one limited systematic review and meta-analysis on the
topic (Li 2016). The Li 2016meta-analysis included seven studies:
four LLLT versus placebo and three LLLT in conjunction with a
splint versus placebo. Six of the studies were included within this
review, one was excluded for comparing LLLT with a splint versus
a splint with no placebo (Yagci 2009). Li 2016 meta-analysed
LLLT versus placebo alongside LLLT in conjunction with another
therapy versus placebo, therefore the results should be interpreted
with caution. Li 2016 found that LLLT improved grip strength,
VAS pain, and sensory nerve motor amplitude.
The findings in this review are in agreement with systematic re-
views of LLLT for the painmanagement of other pathologies (non-
specific low-back pain, neck pain, and orthodontic pain), which
concluded that there were insufficient data to draw firm conclu-
sions (Kadhim-Saleh 2013; Li 2015; Ren 2015; Yousefi-Nooraie
2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Limited and very low-quality evidence exists on the effects of low-
level laser therapy (LLLT) in the treatment of carpal tunnel syn-
drome (CTS). The included trials were of very low quality and
found no data to support any clinical effect of LLLT in treat-
ing CTS. Only visual analogue scale (VAS) pain and finger-pinch
strength meet previously published minimal clinically important
differences (Kelly 2001; Villafañe 2014), but these are likely to
be overestimates of effect given the small studies and significant
risk of bias. There is low- or very low-quality evidence to suggest
that LLLT may be less effective than ultrasound in the manage-
ment of CTS for short-term, clinically significant improvements
in pain and finger-pinch strength.With regards to ultrasound, one
Cochrane systematic review has previously concluded that there is
only poor-quality evidence from very limited data to suggest that
ultrasound may be more effective than placebo for either short-
or long-term symptom improvement in people with CTS (Page
2013). Both reviews highlight the low quality of evidence for these
interventions.
There is insufficient evidence to indicate whether LLLT is more
or less effective than placebo or ultrasound in the management
of CTS at long-term follow-up, based on improvement in clinical
findings and nerve conduction studies. The available evidence is
of very low quality and as such it is uncertain whether LLLT
improves or worsens any of the primary or secondary outcomes
reported. There is insufficient evidence to support or refute greater
benefit with LLLT than other types of non-surgical treatment in
the management of CTS.
Implications for research
Any further research of LLLT should be definitive, blinded, and of
high quality. The existing very low-quality evidence does not need
replicating. Trials should assess the long-term effects of treatment.
Trials should report adverse events as an outcome. Future ran-
domised controlled trials of LLLTversus placebo are first needed to
ascertain any significant therapeutic effect of LLLT. Trials should
ensure an adequate method of random sequence generation and
allocation concealment. Blindingmethods of participants, person-
nel, and outcome assessors need to be fully described and blind-
ing success assessed (such as by asking participants to indicate
which intervention they believe they received). Patient-oriented
and healthcare planning-oriented outcomes should be included.
Appropriate methods such as multiple imputation, ’best-worst’
case scenario and ’worst-best’ case scenario sensitivity analysis to
handle missing data need to be performed. More trials assessing
LLLT versus other non-surgical treatments need to adopt blind-
ing of participants and personnel. Any future trials should be
conducted and reported according to the CONSORT statement
(Schulz 2011).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aigner 1999
Methods Randomised controlled trial
Participants Country: Germany
Number randomised: 26
Postrandomisation dropouts: 0
Mean age: 54 years
Females: 20 (77%)
Inclusion criteria:
• Clinical evidence of CTS
Exclusion criteria:
• Diabetes mellitus
• Chronic alcoholism
• Previous operation for CTS
Interventions Group 1: LLLT (n = 13)
Group 2: placebo (n = 13)
Intervention (group 1): 5 mW helium-neon laser, 15 s at each point (632.6 nm wave-
length) at 6 acupuncture points around the wrist for 15 s at each point
Comparator (group 2): placebo laser
Outcomes Paraesthesia in digits, night pain, activity associated pain, Tinel’s sign, nerve conduction
velocity, distal latency, total potential (did not specify motor or sensory)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “single-blind study.”
Comment: placebo laser used, participants likely blinded
but healthcare providers not
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “single-blind study”
Comment: further details not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
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Aigner 1999 (Continued)
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes that would gener-
ally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Unclear risk Unclear if free of vested interest bias, information not
available
Atya 2011
Methods Randomised controlled trial
Participants Country: Egypt
Number randomised: 30
Postrandomisation dropouts: 0
Mean age: 38 years
Females: 30 (100%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Secondary entrapment neuropathies
• Axonal degeneration
• Previous LLLT
• Steroid injection or regular analgesic for CTS
• Thyroid disease
• Diabetes
• Pregnancy
• Systemic peripheral neuropathy
Interventions Group 1: LLLT (n = 15)
Group 2: tendon and nerve gliding exercises (n = 15)
Intervention: gallium-aluminium-arsenide laser (Enraf, Endolaser) wavelength 830 nm,
output power 30 mW. Total dose per treatment 9 J, accumulated dose 72 J
Comparator: tendon gliding exercises
Outcomes VAS (pain), grip strength,NCS (motor latency, sensory latency, sensory nerve conduction
velocity)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available
Allocation concealment (selection bias) Unclear risk Comment: information not available
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Atya 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding of participants not possible due to
different intervention types
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Unclear risk Comment: information not available
Bakhtiary 2004
Methods Randomised controlled trial
Participants Country: Iran
Number randomised: 50
Postrandomisation dropouts: 0
Mean age: 46 years
Females: information not available
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Secondary entrapment neuropathy
• Axonal degeneration
• Previously treated with ultrasound, LLLT, steroid injection
• NSAID/analgesic treatment
• Thyroid disease
• Diabetes
• Systemic peripheral neuropathy
Interventions Group 1: LLLT (n = 25)
Group 2: ultrasound (n = 25)
Intervention LLLT: 9 J infrared laser diode, 830 nm at 5 points (1.8 J/point)
Comparator ultrasound: frequency of 1 MHz and intensity of 1.0 W/cm2, Enraf
Sonopuls 434 machine
Outcomes VAS, grip strength, finger-pinch strength, NCS (sensory latency and amplitude, motor
latency, and amplitude)
Notes Short-term follow-up (< 3 months)
Risk of bias
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Bakhtiary 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated randomisation list”
Allocation concealment (selection bias) Low risk Quote: “sealed numbered envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The staff who assessed the outcomes were differ-
ent from the staff administering the treatments and they
were blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Low risk Quote: “grant from Semnan Medical Sciences Univer-
sity”
Vested interest bias low risk
Casale 2013
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 20
Postrandomisation dropouts: 0
Mean age: 38 years
Females: 10 (50%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Abnormal findings in ulnar NCS, such as in cases of polyneuropathies of various
aetiology (diabetic, uraemic) and more proximal neuropathies
Interventions Group 1: LLLT (n = 10)
Group 2: transcutaneous electrical nerve stimulation (n = 10)
1 group was treated with sessions of 30 minutes of transcutaneous electrical stimulation
set to administer rectangular waves of 80 ms width, 100 Hz frequency with intensity
below muscle contraction, on pregel electrodes 35 × 45 mm place on the carpal ligament
and proximally along the course of the median nerve. The other group was treated with
combined 830-1064 nm Laser consisting of a radiation dose of 250 J/cm delivered to
the skin overlying the course of the median nerve at the wrist for 100 s at 25 W
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Casale 2013 (Continued)
Outcomes VAS (pain), NCS (motor latency and sensory nerve conduction velocity)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were assigned to one or other of the two
treatment groups by means of a computer-aided allocation
system”
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: stated participants blinded but did not state
method of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Staff administered treatment and outcome mea-
sures were blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No pro-
tocol or trial registry entry identified
Other bias Unclear risk Comment: information not available
Chang 2008
Methods Randomised controlled trial
Participants Country: Taiwan
Number randomised: 40
Postrandomisation dropouts: 0
Mean age: 47 years
Females: information not provided
Inclusion criteria:
• Clinical evidence of CTS
• No surgery to the wrist
• First onset of CTS > 1 year ago with repeated episodes
• Never previously had laser therapy
Exclusion criteria:
• Rheumatoid arthritis
• History of metabolic disease
• Paralysed limbs caused by stroke
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Chang 2008 (Continued)
Interventions Group 1: LLLT (n = 20)
Group 2: placebo (n = 20)
Intervention: “Painless light PL-830; Advanced Chips & Products Corp., Hillside, NJ,”
emitted 2 light beams spaced 2.5 cm apart via 2 laser diodes. The operational wavelength
was 830 nm. Its output frequency and output power were set to be 10 Hz and 60 (2
× 30) mW, respectively Treatment dose was 9.7 J/cm2. The laser was placed directly
above the transverse carpal ligament (between the pisiform and navicular bones) on the
person’s affected wrist. The treatments were conducted by the same physical therapist
over 2 weeks for 10 min per day, 5 days per week
Comparator: placebo laser
Outcomes SSS, FSS, grip strength, finger-pinch strength, NCS (sensory and motor latency)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of randomisation not given
Allocation concealment (selection bias) Unclear risk Comment: method of allocation concealment not given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: authors stated that a “double-blind experi-
ment” was performed but no information provided on
methods of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: authors stated that a “double-blind experi-
ment” was performed but no information provided on
methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Low risk Quote: “The authors are grateful to the National Science
Council of the Republic of China for financially support-
ing this research”
No vested interest bias
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Dakowicz 2011
Methods Randomised controlled trial
Participants Country: Poland
Number randomised: 38
Postrandomisation dropouts: 0
Mean age: 51 years
Females: 35 (92%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
None provided
Interventions Group 1: LLLT (n = 18).
Group 2: pulsed magnetic frequency (n = 20)
Intervention: gallium-arsenide laser, “Physioter; D-50, ZEMMARP Electronic Krakow,
Poland,” wavelength 904 nm, power density 150 mW. The total energy per treatment
50 J
Comparator: pulsed magnetic frequency, Magnetronic MF-10 “Elektronika Elektrome-
dycyna Otwock, Poland” frequency 10-40 Hz, induction 1.0-5.0 mTesla
Outcomes Day and night paraesthesia, day and night pain, VAS, Phalen’s test, Tinel’s test, armband
test, NCS (sensory and motor latency)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not provided
Allocation concealment (selection bias) Unclear risk Comment: information not provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants not blinded to intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Unclear risk Comment: information not provided
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Dincer 2009
Methods Randomised controlled trial
Participants Country: Turkey
Number randomised: 60 (120 wrists)
Postrandomisation dropouts: n = information not available, 20 wrists
Mean age: 46 years
Females: 60 (100%)
Inclusion criteria:
• Diagnosed with mild to moderate CTS according to the American Association of
Electrodiagnostic Medicine guidelines
Exclusion criteria:
• Severe CTS
• Underlying metabolic disorders such as diabetes mellitus, thyroid or kidney
disease
• Connective tissue disorders
• Malignancy
• Distal radial fracture
• Cervical radiculopathy
• Brachial plexopathy
• Tenosynovitis
• Fibromyalgia
• Any other CTS treatment or surgical procedure during the past year
• Pregnant
Interventions Group 1: wrist splint (n = 34 wrists)
Group 2: wrist splint + ultrasound (n = 30 wrists)
Group 3: wrist splint + LLLT (n = 36 wrists)
Splint: neutral standard light-weight wrist splint worn at night and during aggravating
daytime activities
Ultrasound: administered to each hand for 3min per session, with 10 sessions performed
once per day, 5 times per week for 2 weeks. Ultrasound administered at frequency of 3
MHz and intensity of 1.0 W/cm2 in continuous mode
LLLT: infrared gallium-arsenide diode laser with wavelength 904 nm, frequency range
5-7000 Hz, pulse duration 200 ns, maximum power output 27W,mean power 2.4 mW.
LLLT applied to 3 points over course of median nerve for 30 s at each point, with 10
sessions performed once per day, 5 times per week for 2 weeks
Outcomes VAS, SSS, FSS, patient satisfaction 5-point scale, NCS (motor latency, velocity and
amplitude, sensory velocity and amplitude)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was performed by the use of
numbered envelopes.”
Comment: unclear how, and whether or not, the ran-
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Dincer 2009 (Continued)
domisation sequence adequately generated
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed by the use of
numbered envelopes.”
Comment: unclear whether allocation sequence ade-
quately concealed (i.e. whether numbered envelopes were
sealed and opaque and sequentially numbered)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Ultrasound therapy was administered to each
hand for 3 min per session, on the area over the carpal
tunnel…with aquasonic gel;”
“Laser therapywas applied to three points over the course
of the median nerve at the wrist. The laser probe was
applied directly and perpendicularly in contact with the
skin for 30 sec at each point. At each treatment session,
the patients and physiotherapist wore protective glasses.
”
Comment: different treatment methods and application
make it likely blinding was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “at the first and thirdmonth the assessments were
performed by another physiatrist who was blinded to
treatment modality”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: postrandomisation dropouts with no meth-
ods to handle missing data
Selective reporting (reporting bias) High risk Comment: authors reported numerical outcomes for
some but not all NCS data (motor latency and sensory
velocity reported, for the remainder numerical data not
given). No protocol or trial registry entry identified
Other bias Low risk Quote: “No conflicting financial interest exist.”
Ekim 2007
Methods Randomised controlled trial
Participants Country: Turkey.
Number randomised: 19
Postrandomisation dropouts: 0
Mean age: 52 years
Females: 18 (95%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
• Rheumatoid arthritis
Exclusion criteria:
• Underlying metabolic disorders
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Ekim 2007 (Continued)
• Cervical radiculopathy
• Previous wrist trauma
• Peripheral neuropathies
• Anaesthesia or intractable pain due to CTS
• Steroid injection or physiotherapy in last 3 months
• Thenar atrophy
• Spontaneous activity on NCS of the abductor pollicis brevis muscle
Interventions Group 1: LLLT (n = 10)
Group 2: placebo (n = 9)
Intervention: gallium-aluminium-arsenid laser device (Endolaser 476 Enraf Nonius,
Netherlands); power output 50 mW. Treatment dose 7.5 J and accumulated dose 75 J
Comparator: placebo laser
Outcomes VAS (pain), SSS, FSS, grip strength, NCS (motor latency and amplitude, sensory latency,
and amplitude), Tinel’s sign, Phalen’s sign
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of randomisation not available
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment information not
available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “another physician not blinded to treatment al-
location applied the treatments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a blinded physician unaware of the treatment
allocationperformed the clinical and electrophysiological
parameters at baseline, post treatment and a month 3”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Low risk Quote: “No financial support declared”
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Evcik 2007
Methods Randomised controlled trial
Participants Country: Turkey
Number randomised: 81
Postrandomisation dropouts: 0
Mean age: 46 years
Females: 70 (86%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Severe hand trauma
• Cervical radiculopathy
• Thoracic outlet syndrome
• Neurological, cognitive, inflammatory, or tumoural disorders
Interventions Group 1: LLLT (n = 41)
Group 2: placebo (n = 40)
Intervention: 830 nm aluminium-gallium-arsenide diode laser, maximum power output
450 mW. Laser therapy 7 J per point to 2 points in pulse mode with power density 0.
60 W/cm2 by a pulse frequency 1000 Hz, 30 s irradiation at each point. Total of 10
treatments - once daily, 5 days per week for 2 weeks
Comparator: placebo laser
Outcomes VAS (pain), VAS (pain) night, SSS, grip strength, finger-pinch strength, NCS (motor
latency, velocity and amplitude, sensory latency, velocity, and amplitude)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: allocation given in numbered envelopes, fur-
ther information required for randomisation of envelopes
Allocation concealment (selection bias) Low risk Comment: allocation given in numbered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “patients and physicians were not aware of the
therapy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “physicians were not aware of the therapy...post-
treatment outcome measures were assessed by another
physician”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
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Evcik 2007 (Continued)
Selective reporting (reporting bias) High risk Comment: SSS reported within text but FSS not re-
ported. No protocol or trial registry entry identified
Other bias Unclear risk Vested interest bias unclear: information not available
Fusakul 2014
Methods Randomised controlled trial
Participants Country: Thailand
Number randomised: 66 (112 wrists)
Postrandomisation dropouts: 7 (112 wrists)
Mean age: 51 years
Females: 108/112 wrists (96%)
Inclusion criteria:
• mild to moderate CTS on NCS (as defined by American Association of
Electrodiagnostic Medicine guidelines)
Exclusion criteria:
• Severe CTS
• Underlying metabolic disorders
• Previous distal radius fractures
• Wrist-hand deformities
• Inflammation of joints in hand such as rheumatoid arthritis
Interventions Group 1: LLLT + splint (n = information not available, 56 hands)
Group 2: placebo LLLT + splint (n = information not available, 56 hands)
Intervention: gallium-aluminium-arsenide diode laser with wavelength 810 nm and
power output 50 mW. Dose of treatment 18 J per session. Each participant treated with
laser therapy for 15 sessions in total over 5 weeks
Each participant also prescribed a prefabricated neoprene splint set in neutral position.
All participants were encouraged to use their wrist splints during the night-time and
daytime whenever possible
Comparator: placebo laser
Outcomes VAS, SSS, FSS, grip strength, finger-pinch strength, NCS (sensory latency and ampli-
tude, motor latency, and amplitude)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly allocated into two groups...by using
two sets of previously prepared and randomly enumer-
ated sealed envelopes that specified the treatment meth-
ods”
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Fusakul 2014 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: unclear whether allocation sequence was ade-
quately concealed (i.e. whether numbered envelopes were
sealed and opaque and sequentially numbered)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: authors stated that “double-blind experi-
ment” was performed but no information provided on
methods of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: authors stated that “double-blind experi-
ment” was performed but no information provided on
methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: postrandomisation dropouts with no meth-
ods to handle missing data
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Low risk Quote: “Each author certifies that he or she has no com-
mercial associations that might pose a conflict of interest
in connection with the submitted article...there was no
external funding source outside of the University’s Re-
search Funding Program.”
Irvine 2004
Methods Randomised controlled trial
Participants Country: Canada
Number randomised: 15
Postrandomisation dropouts: 0
Mean age: 46 years
Females: 12 (80%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Marked axonal loss on NCS
• Arthritic disease
• Previous wrist trauma
• Previous carpal tunnel release
Interventions Group 1: LLLT (n = 7)
Group 2: placebo (n = 8)
Intervention: gallium-aluminium-arsenide laser with wavelength 860 nm, dosage 6 J/
cm2 over carpal tunnel
Comparator: placebo laser
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Irvine 2004 (Continued)
Outcomes SSS, FSS, Purdue pegboard test, NCS
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was done using the random-
number generation function”
Allocation concealment (selection bias) Low risk Quote: “A staff person not involved in the rest of the
study performed the randomization,” “Neither the in-
vestigators nor the subjects were aware of the treatment
assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The physical therapist administering the treat-
ments was not involved in the outcome measure assess-
ment.” “Neither the investigators nor the subjects were
aware of the treatment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither the investigators nor the subjects were
aware of the treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Low risk Vested interest bias low. Disclosures: Physiotherapy
Foundation of Canada financial support
Jiang 2011
Methods Randomised controlled trials
Participants Country: Taiwan
Number randomised: 90
Postrandomisation dropouts: 3
Mean age: 48 years
Females: information not available
Inclusion criteria:
• Clinical idiopathic CTS with repeated pain for > 1 year
Exclusion criteria:
• Medical histories of systemic disease
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Jiang 2011 (Continued)
• Previous surgery
• Other treatments such as anti-inflammatory medicine, acupuncture, and physical
therapy
Interventions Group 1: LLLT (n = 45)
Group 2: placebo (n = 43)
Intervention: painless light PL-830 laser (Advanced Chips & Products Corp., USA)
with wavelength 830 nm, output frequency 10 Hz, mean power 60 mW (2 × 30 mW),
treatment dosage 9.7 J/cm2. 2 diode lasers emitted laser beam (irradiated area 370 mm
2) on palm side of wrist (between the pisiform and navicular bones). LLLT executed for
10 min, 5 times per week for 2 weeks
Comparator: placebo laser
Outcomes VAS, SSS, NCS (sensory latency, motor latency), Phalen’s test, Tinel’s sign
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of randomisation not available
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: authors stated blinding but no information
available on method of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the four assessments, pain, symptoms, neuro-
logical signs and NCS were blind to one evaluator.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: postrandomisation dropouts
Selective reporting (reporting bias) High risk Comment: SSS reported but FSS not reported. No pro-
tocol or trial registry entry identified
Other bias Low risk Quote: “Financial support from the president of the na-
tional Taiwan university… also supported in part by the
national science council”
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Lazovic 2014
Methods Randomised controlled trial
Participants Country: Serbia
Number randomised: 79
Postrandomisation dropouts: 0
Mean age: 52 years
Females: 70 (89%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
• Aged > 18 years
Exclusion criteria:
• Severe CTS on NCS (CMAP < 3.8 mV or severe reduction of EMG interference
pattern or denervation, or both)
• Thenar atrophy
• Severe pain intensity > 7 based on VAS
Interventions Group 1: LLLT (n = 40)
Group 2: placebo (n = 39)
Intervention: aluminium-gallium-arsenide diode laser (Medicolaser 637) wavelength
780 nm, power output 30 mW continuous wave, array 0.785 cm2, power density 38.2
mW/cm2 applied in contact with 4 points perpendicularly on skin on volar side of wrist
over carpal tunnel area for 90 s/point (2.7 J, 3.4 J/cm2/point). Total of 20 treatments
with following schedule: 10 treatments once per day, 5 days per week for 2 weeks, fol-
lowed by 10 treatments every other day for 3 weeks
Comparator: placebo laser
Outcomes VAS (pain) (categorical: mild/moderate/severe), Tinel’s sign, NCS (motor latency, sen-
sory velocity)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: randomly allocated using numbered en-
velopes
Allocation concealment (selection bias) Low risk Quote: “allocated using the numbered envelopes
method”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both physicians, as well as the participants and
the staff who applied the procedures, were unaware of
the therapy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “NCS evaluations were performed by another
physician...unaware of the therapy”
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Lazovic 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes which would gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Low risk Quote: “no competing financial interests exist”
Lucantoni 1992
Methods Randomised controlled trial.
Participants Country: Italy
Number randomised: 40
Postrandomisation dropouts: 0
Mean age: information not available
Females: 40 (100%)
Inclusion criteria:
• Clinical and electrophysiological evidence of bilateral CTS
• Aged 40-60 years
• Female
Exclusion criteria:
• Secondary forms of CTS
• Metabolic/rheumatological disease
• Median nerve sensorimotor deficit
• Distal latency values 6 ms
Interventions Group 1: LLLT (n = 20)
Group 2: steroid injection (n = 20)
Intervention: helium-neon laser, frequency 3000 Hz
Comparator: methylprednisolone acetate 20 mg
Outcomes Improvement in pain and paraesthesia (0-3 scale), NCS (motor latency and sensory
latency)
Notes Short-term (< 3 months) and long-term (6 months) follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available
Allocation concealment (selection bias) Unclear risk Comment: information not available
62Low-level laser therapy for carpal tunnel syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lucantoni 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding of participants to treatment not per-
formed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomeswhichwould gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Unclear risk Comment: information not available
Pratelli 2015
Methods Randomised controlled trial
Participants Country: Italy
Number randomised: 42
Postrandomisation dropouts: 0
Mean age: 54 years
Females: 29 (69%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Congenital coagulopathy, anticoagulant therapy
• Previous treatments < 3 months
• Only weakness symptoms
• Concomitant tumours
• Systemic neurological and rheumatological pathologies
Interventions Group 1: LLLT (n = information not available, 35 hands)
Group 2: fascial manipulation (n = information not available, 35 hands)
Intervention: M300 level laser with wavelength of 780-830 nm, power output 1000-
3000 mW
Comparator: 3 sessions of fascial manipulation for 45 min once per week for 3 weeks.
Technique involved deep friction over specific points (centre of co-ordinations or centre of
fusions) selected by a clinical examination that involved specificmovement and palpatory
verification. Therapist used elbow and knuckles to create friction on identified points.
Each point had surface area < 2 cm2. Friction maintained for mean time of 3 min (range:
2-4 min) as indicated by technique. Number of points treated in each session 4-8 (mean
6)
Outcomes VAS, SSS, FSS
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Pratelli 2015 (Continued)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The investigator flipped a coin to determine
whether the participant should go into group A or B”
Comment: inadequate method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Only one degree of blinding was possible due to
the different modality of treatment”
Comment: participants not blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All participants were evaluated by physician P.
C. who was blinded from the original patient group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes which would gener-
ally be assessed were reported. No protocol or trial reg-
istry entry identified
Other bias Unclear risk Comment: information not available
Rayegani 2013
Methods Randomised controlled trial
Participants Country: Iran
Number randomised: 50
Postrandomisation dropouts: 0
Mean age: 49 years
Females: information not available
Inclusion criteria:
• Presence of pain/paraesthesia in distribution of median nerve
• Positive clinical provocative test for CTS (Tinel’s test, Phalen’s test)
• Electrophysiological evidence of mild or moderate median nerve lesion at wrist
(mild: sensory nerve latency > 3.5 ms at third digit; moderate: sensory nerve latency >
3.5 ms at third digit and median motor latency > 4.2 ms)
Exclusion criteria:
• Presence of conditions affecting nerve conduction or abnormal findings in other
nerves such as the presence of polyneuropathies, as well as proximal neuropathies
affecting nerve trunks, plexus, or cervical roots diagnosed by physical examinations,
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Rayegani 2013 (Continued)
and comprehensive electrodiagnostic studies
Interventions Group 1: LLLT + splinting + vitamin B6 (n = 18)
Group 2: placebo LLLT + splinting vitamin B6 (n = 15)
Group 3: splinting + vitamin B6 (n = 17)
Intervention:Multiwave Locked System indium laser ofM1 type, continuous waves with
wavelength 880 nm, frequency 1000 Hz. Each session lasted 10 minutes, consisting of
radiating dose delivered to 5 points of skin overlying course of median nerve, delivered
for 120 seconds at each point along course of median nerve in each hand
Hands of participants in all 3 groups were splinted with a static wrist splint fixed in 0°
of wrist flexion. Participants instructed to use splint daily
Information regarding dose of vitamin B6 not provided.
Comparator: placebo laser
Outcomes VAS, SSS, FSS, NCS (motor amplitude and latency, sensory amplitude, and latency)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “They were randomly assigned to one of three
treatment groups by means of the random number table”
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients were blinded to the treatment used in
Laser and Sham Laser group;” “This study was designed
as single blinded controlled.”
Comment: personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: outcome assessors not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: all important outcomes which would gener-
ally be assessed were reported. No protocol or trial reg-
istry entry identified
Other bias Unclear risk Comment: information not available
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Rodrigues 2013
Methods Randomised controlled trial
Participants Country: Cuba
Number randomised: 42
Postrandomisation dropouts: 0
Mean age: 50-59 years
Females: 40 (95%)
Inclusion criteria:
• Clinical evidence of CTS
• < 6 months’ duration
Exclusion criteria:
• Conditions that contraindicated rehabilitation treatment or administration of
NSAIDs, or both
Interventions Group 1: LLLT (n = 21)
Group 2: splint + NSAIDs (n = 21)
Intervention: Expert laserterapia (Physiomed), power output 700 mW, wavelength 785
nm, treatment dosage 6 J/cm2
Comparator: postural hand splint in neutral wrist + NSAIDs
Outcomes Pain, NCS, neurophysiological injury (as defined by study authors)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding of participants to treatment not per-
formed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes which would gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Unclear risk Comment: information not available
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Saeed 2012
Methods Randomised controlled trial
Participants Country: Pakistan
Number randomised: 100
Postrandomisation dropouts: 0
Mean age: 36 years
Females: 55 (55%)
Inclusion criteria:
• Unilateral CTS
• > 4 months’ duration
• No other compressive neuropathy or general neuropathy on NCS
Exclusion criteria:
• History of fracture
• Steroid injection
• Surgical decompression
Interventions Group 1: LLLT (n = 50)
Group 2: ultrasound (n = 50)
Intervention: 9 J infrared laser diode (Enraf, Endolaser 830 nm) at 1.8 J/point over wrist
Comparator: ultrasound therapy at 1MHzand intensity 1.0W/cm2 withEnraf Sonopuls
492
Outcomes VAS, SSS
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer generated randomization was done
by the statistician...”
Allocation concealment (selection bias) Low risk Quote: “...and it was given to the physiotherapy dept in
two sets of sealed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The staff who assessed the outcomes were differ-
ent from the staff administering the treatments and they
were blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes which would gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
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Saeed 2012 (Continued)
Other bias Unclear risk Comment: information not available
Shooshtari 2008
Methods Randomised controlled trial
Participants Country: Iran
Number randomised: 80
Postrandomisation dropouts: 0
Mean age: 48 years
Females: 73 (91%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Trauma to hand or neck
• Systemic disease
• Pregnancy
• Hand oedema
• Obesity
• Previous carpal bone fracture or surgery
• Severe NCS findings
Interventions Group 1: LLLT (n = 40)
Group 2: placebo (n = 40)
Intervention: low power laser waves by physiolaser Olympic with multicluster probe
(Germany) with wavelength 785 nM and EC Nogier frequencies (4672 Hz and 1168
Hz) in the form of pulse and energy 9-11 J/cm2 and 400 mw at anterior side of wrist
and palm for 15 sessions (5 times per week)
Comparator: placebo laser
Outcomes VAS (pain), grip strength, NCS (motor and sensory latency, sensory nerve conduction
velocity)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: randomisation method not available
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment method not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available
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Shooshtari 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes which would gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Unclear risk Vested interest bias information not available
Soltani 2013
Methods Randomised controlled trial
Participants Country: Turkey
Number randomised: 33
Postrandomisation dropouts: 0
Mean age: 47 years
Females: 28 (85%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
Exclusion criteria:
• Secondary CTS
• Previous steroid injection
• Previous LLLT
• Severe symptoms
• Willing to undergo surgery
Interventions Group 1: LLLT (n = 16)
Group 2: steroid injection (n = 17)
Intervention: low potent laser characterised with amplitude 775 nm, frequency 6500 Hz
and intensity 20 J/cm2
Comparator: hydrocortisone 50 mg
Outcomes VAS, NCS (motor and sensory distal latency, motor and sensory amplitude)
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomly assigned to the groups
at the coordination room of the research center according
to a computer-generated randomization list.”
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Soltani 2013 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants not blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Outcome assessments were performed by
blinded study physicians.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Unclear risk Comment: some important outcomes which would gen-
erally be assessed were not reported. No protocol or trial
registry entry identified
Other bias Unclear risk Comment: information not available
Tascioglu 2012
Methods Randomised controlled trial
Participants Country: Turkey
Number randomised: 60
Postrandomisation dropouts: 0
Mean age: 50 years
Females: 46 (76%)
Inclusion criteria:
• Clinical and electrophysiological evidence of CTS
• < 6 months’ duration
Exclusion criteria:
• Wrist injection
• Surgery or fracture
• Accompanying conditions that mimic CTS or interfere with its evaluation
• Underlying disorders associated with CTS
• Anatomical variation of the median nerve
• Previous physiotherapy
Interventions Group 1: LLLT, dosage 90 J (n = 20)
Group 2: LLLT, dosage 45 J (n = 20)
Group 3: placebo (n = 20)
Intervention: aluminium-gallium-arsenide diode laser device (Endolaser 476, Enraf-
Nonius, Netherlands) with power output 50 mW and wavelength 830 nm. Diameter
of laser beam at treatment point 1 mm. Laser set to deliver continuous form of energy.
A total of 5 points across median nerve trace irradiated with laser probe. Participants
in group 1 received irradiation at each point of skin overlying median nerve on volar
side at the wrist. A 2-min irradiation at each point (total 10 min) was considered as 1
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Tascioglu 2012 (Continued)
irradiation at each point. Dose per tender joint 1.2 J, total dose per treatment 6 J, and
accumulated dose for 15 treatments 90 J. Group 2 received 3 J dose per treatment (45 J
total)
Comparator: placebo laser
Groups 1 and 2 were combined for further statistical analysis
Outcomes VAS, SSS, FSS, grip strength, motor distal latency and velocity, sensory velocity, cross-
sectional ultrasound scan findings
Notes Short-term follow-up (< 3 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned to three groups by a secure
system of numbered 1-3 opaque closed envelopes. The
physician who assigned the patients was blinded to the
treatment they would receive.”
Allocation concealment (selection bias) Low risk Quote: “randomly assigned to three groups by a secure
system of numbered 1-3 opaque closed envelopes. The
physician who assigned the patients was blinded to the
treatment they would receive.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information regarding blinding of partici-
pants not available
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a blinded physician unaware of the treatment
allocation performed the clinical assessments at baseline
and at the end of therapy.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported. No
protocol or trial registry entry identified
Other bias Unclear risk Vested interest bias information unavailable
Tikiz 2013
Methods Randomised controlled trial
Participants Country: Turkey.
Number randomised: 60
Postrandomisation dropouts: 8
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Mean age: 48 years
Females: 46 (88%)
Inclusion criteria:
• Clinical evidence of CTS
• > 6 weeks’ duration
Exclusion criteria:
• CTS predisposed by aetiological factors
• NSAIDs
• Steroid injection or physiotherapy in previous month
• Cervical radiculopathy
• Polyneuropathy
• Proximal neuropathy of the median nerve
• Ulnar neuropathy
Interventions Group 1: ultrasound (n = 14)
Group 2: ultrasound placebo (n = 12)
Group 3: LLLT (n = 13)
Group 4: LLLT placebo (n = 13)
Intervention LLLT: aluminium-gallium-arsenide laser “Endolaser 476 Enraf-Nonus,
Netherlands” with power output 30 mW, wavelength 830 nm
Intervention ultrasound: pulsed ultrasound (Sonicate 730, Mettler Electronics, USA) at
frequency 3 MHz, dosage 1 W/cm2
Comparator: placebo laser
Comparator 2: placebo ultrasound
Outcomes VAS, numbness VAS, hand grip strength, SSS, FSS, NCS (motor distal latency and
velocity, sensory velocity), cross-sectional ultrasound scan findings
Notes Short-term (< 3 month) and long-term (12 month)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Arrivals by order of 1, 2, 3, 4 was given to a
group, then again...”
Comment: inappropriate randomisation method
Allocation concealment (selection bias) High risk Quote: “Arrivals by order of 1, 2, 3, 4 was given to a
group, then again...”
Comment: inappropriate randomisation method
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information unavailable
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information unavailable
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all important outcomes were reported
Selective reporting (reporting bias) Unclear risk Comment: all NCS outcomes that would usually be re-
ported were not reported. Important outcome measures
otherwise were reported. No protocol or trial registry en-
try identified
Other bias Low risk Quote: “authors have not reported any conflict of inter-
est.”
CMAP: compound muscle action potential; CTS: carpal tunnel syndrome; EMG: electromyography; FSS: Functional Status Scale;
LLLT: low-level laser therapy; n: number of participants; NCS; nerve conduction studies; NSAID: non-steroidal anti-inflammatory
drug; SSS: Symptom Severity Score; VAS: visual analogue score.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barbosa 2016 LLLT + splint vs splint alone (no placebo LLLT)
Branco 1999 LLLT + TENS or acupuncture
Kotb 2014 LLLT + splint + ultrasound vs splint + steroid injection
Montes-Molina 2011 Included participants with a history of previous surgery for CTS
Naeser 2002 Included participants with a history of previous surgery for CTS
Padua 1999 Not a randomised controlled trial
Tamam 2012 Paper initially stated it studied 56 people who were randomised to 2 groups of 18. The remaining participants
were not discussed. Further information not available. We contacted trial authors for further information;
however, this was not provided. Therefore, insufficient information to assess eligibility as type of participants
not clearly described
Yagci 2009 LLLT + splint vs splint alone (no placebo LLLT)
CTS: carpal tunnel syndrome; LLLT: low level laser therapy; TENS: transcutaneous electrical nerve stimulation.
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D A T A A N D A N A L Y S E S
Comparison 1. Low-level laser therapy (LLLT) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom Severity Score, short
term (≤ 3 months)
7 327 Mean Difference (IV, Random, 95% CI) -0.36 [-0.78, 0.06]
2 Functional Status Scale 5 159 Mean Difference (IV, Random, 95% CI) -0.56 [-1.03, -0.09]
3 VAS pain 7 392 Mean Difference (IV, Random, 95% CI) -1.47 [-2.36, -0.58]
4 Grip strength (kg) 5 286 Mean Difference (IV, Random, 95% CI) 2.58 [1.22, 3.95]
5 Finger-pinch strength (kg) 2 121 Mean Difference (IV, Random, 95% CI) 0.94 [0.43, 1.44]
6 Motor nerve latency (ms) 7 446 Mean Difference (IV, Random, 95% CI) -0.09 [-0.16, -0.03]
7 Sensory nerve latency (ms) 5 307 Mean Difference (IV, Random, 95% CI) -0.10 [-0.15, -0.06]
8 Sensory nerve velocity (m/s) 2 139 Mean Difference (IV, Random, 95% CI) 1.48 [-5.68, 8.65]
Comparison 2. Low-level laser therapy (LLLT) versus ultrasound
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom Severity Score 2 127 Mean Difference (IV, Random, 95% CI) 0.43 [0.36, 0.50]
2 Functional Status Scale 2 127 Mean Difference (IV, Random, 95% CI) 0.35 [0.29, 0.41]
3 Visual analogue score 3 177 Mean Difference (IV, Random, 95% CI) 2.81 [1.21, 4.40]
4 Grip strength (kg) 2 77 Mean Difference (IV, Random, 95% CI) -0.89 [-4.30, 2.52]
5 Motor nerve latency (ms) 3 177 Mean Difference (IV, Random, 95% CI) 0.61 [0.27, 0.95]
6 Sensory nerve latency (ms) 3 177 Mean Difference (IV, Random, 95% CI) 0.43 [-0.01, 0.87]
7 Motor amplitude (mV) 2 77 Mean Difference (IV, Random, 95% CI) -1.90 [-3.63, -0.18]
8 Sensory latency - preanalysis
(ms)
3 Mean Difference (Random, 95% CI) 0.43 [-0.01, 0.87]
9 Sensory latency, intracluster
correlation coefficient 1.00
(ms)
3 Mean Difference (Random, 95% CI) 0.47 [0.39, 0.55]
Comparison 3. Low-level laser therapy (LLLT) versus steroid injection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Motor latency (ms) 2 73 Mean Difference (IV, Random, 95% CI) -0.04 [-0.39, 0.30]
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Analysis 1.1. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 1 Symptom Severity
Score, short term (≤ 3 months).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 1 Symptom Severity Score, short term (≤ 3 months)
Study or subgroup Favours LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 20 1.76 (0.057) 20 2.61 (0.077) 16.6 % -0.85 [ -0.89, -0.81 ]
Ekim 2007 10 1.64 (0.64) 9 1.91 (0.364) 13.8 % -0.27 [ -0.73, 0.19 ]
Evcik 2007 41 2.15 (0.18) 40 2.15 (0.2) 16.5 % 0.0 [ -0.08, 0.08 ]
Irvine 2004 7 1.9 (0.6) 8 1.9 (0.4) 13.2 % 0.0 [ -0.52, 0.52 ]
Jiang 2011 45 -0.83 (0.32) 42 -0.18 (0.49) 16.1 % -0.65 [ -0.83, -0.47 ]
Tascioglu 2012 40 1.67 (0.631) 20 1.85 (0.656) 14.9 % -0.18 [ -0.53, 0.17 ]
Tikiz 2013 13 2.3 (1.1) 12 2.9 (1.3) 9.0 % -0.60 [ -1.55, 0.35 ]
Total (95% CI) 176 151 100.0 % -0.36 [ -0.78, 0.06 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 338.11, df = 6 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours LLLT Favours placebo
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Analysis 1.2. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 2 Functional Status
Scale.
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 2 Functional Status Scale
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 (1) 20 1.38 (0.054) 20 2.45 (0.1275) 25.5 % -1.07 [ -1.13, -1.01 ]
Tikiz 2013 13 2.2 (1) 12 3.2 (1) 15.0 % -1.00 [ -1.78, -0.22 ]
Tascioglu 2012 40 1.72 (0.598) 20 2.16 (0.611) 22.9 % -0.44 [ -0.77, -0.11 ]
Ekim 2007 10 1.75 (0.525) 9 2.13 (0.375) 21.5 % -0.38 [ -0.78, 0.03 ]
Irvine 2004 7 1.8 (0.9) 8 1.5 (0.6) 15.0 % 0.30 [ -0.49, 1.09 ]
Total (95% CI) 90 69 100.0 % -0.56 [ -1.03, -0.09 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 35.22, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours LLLT Favours placebo
(1) Forest plot of LLLT versus placebo showing lower FSS in LLLT group
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Analysis 1.3. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 3 VAS pain.
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 3 VAS pain
Study or subgroup Favours LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 20 3 (4.05) 20 6 (5) 6.5 % -3.00 [ -5.82, -0.18 ]
Ekim 2007 10 3.3 (0.9) 9 4.3 (0.6) 16.5 % -1.00 [ -1.68, -0.32 ]
Evcik 2007 41 2.28 (0.76) 40 2.88 (2) 16.6 % -0.60 [ -1.26, 0.06 ]
Jiang 2011 (1) 45 -2.92 (1.61) 42 -1.04 (1.12) 17.0 % -1.88 [ -2.46, -1.30 ]
Shooshtari 2008 40 4.98 (0.12) 40 7.62 (0.4) 18.2 % -2.64 [ -2.77, -2.51 ]
Tascioglu 2012 40 3.93 (1.82) 20 4.55 (1.39) 15.8 % -0.62 [ -1.45, 0.21 ]
Tikiz 2013 13 3.18 (2.7) 12 4.37 (2.49) 9.4 % -1.19 [ -3.22, 0.84 ]
Total (95% CI) 209 183 100.0 % -1.47 [ -2.36, -0.58 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 79.64, df = 6 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Not applicable
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(1) Forest plot of LLLT versus placebo showing lower VAS pain in LLLT group
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Analysis 1.4. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 4 Grip strength (kg).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 4 Grip strength (kg)
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 20 21.19 (4.12) 20 17.38 (3.56) 32.8 % 3.81 [ 1.42, 6.20 ]
Evcik 2007 (1) 41 22.8 (6.9) 40 19.6 (7.3) 19.5 % 3.20 [ 0.11, 6.29 ]
Shooshtari 2008 (2) 40 22.86 (5.13) 40 21.52 (6.05) 30.9 % 1.34 [ -1.12, 3.80 ]
Tascioglu 2012 40 25.23 (7.43) 20 24.48 (7.43) 11.7 % 0.75 [ -3.24, 4.74 ]
Tikiz 2013 13 18.3 (9.4) 12 14.2 (5.9) 5.0 % 4.10 [ -2.00, 10.20 ]
Total (95% CI) 154 132 100.0 % 2.58 [ 1.22, 3.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.20, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Not applicable
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Favours placebo Favours LLLT
(1) Forest plot of LLLT versus placebo showing higher grip strength in LLLT group
(2) Forest plot of LLLT versus placebo showing higher grip strength in LLLT group
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Analysis 1.5. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 5 Finger-pinch
strength (kg).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 5 Finger-pinch strength (kg)
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 (1) 20 5.33 (1.33) 20 4.35 (1.09) 44.5 % 0.98 [ 0.23, 1.73 ]
Evcik 2007 (2) 41 5.7 (1.6) 40 4.8 (1.5) 55.5 % 0.90 [ 0.22, 1.58 ]
Total (95% CI) 61 60 100.0 % 0.94 [ 0.43, 1.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00027)
Test for subgroup differences: Not applicable
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Favours placebo Favours LLLT
(1) Forest plot of LLLT versus placebo showing higher pinch strength in LLLT group
(2) Forest plot of LLLT versus placebo showing higher pinch strength in LLLT group
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Analysis 1.6. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 6 Motor nerve latency
(ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 6 Motor nerve latency (ms)
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 20 3.87 (0.3) 20 4.1 (0.21) 15.3 % -0.23 [ -0.39, -0.07 ]
Ekim 2007 10 3.3 (0.7) 9 3.1 (0.5) 1.3 % 0.20 [ -0.34, 0.74 ]
Evcik 2007 (1) 41 4.1 (0.7) 40 4.2 (1.08) 2.5 % -0.10 [ -0.50, 0.30 ]
Jiang 2011 45 -0.2 (0.2) 42 -0.12 (0.15) 71.8 % -0.08 [ -0.15, -0.01 ]
Lazovic 2014 40 4.69 (1.51) 39 4.99 (2.01) 0.6 % -0.30 [ -1.09, 0.49 ]
Shooshtari 2008 40 3.94 (0.51) 40 3.94 (0.52) 7.7 % 0.0 [ -0.23, 0.23 ]
Tascioglu 2012 40 4.09 (1.38) 20 4.05 (1.35) 0.7 % 0.04 [ -0.69, 0.77 ]
Total (95% CI) 236 210 100.0 % -0.09 [ -0.16, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.08, df = 6 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Favours LLLT Favours placebo
(1) Forest plot of LLLT versus placebo showing lower motor nerve latency in LLLT group
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Analysis 1.7. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 7 Sensory nerve
latency (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 7 Sensory nerve latency (ms)
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chang 2008 (1) 20 3.67 (0.21) 20 3.8 (0.11) 17.0 % -0.13 [ -0.23, -0.03 ]
Ekim 2007 (2) 10 1.9 (0.4) 9 1.8 (0.3) 1.8 % 0.10 [ -0.22, 0.42 ]
Evcik 2007 (3) 41 3 (0.5) 40 3.1 (0.6) 3.2 % -0.10 [ -0.34, 0.14 ]
Jiang 2011 45 -0.18 (0.13) 42 -0.07 (0.11) 71.9 % -0.11 [ -0.16, -0.06 ]
Shooshtari 2008 40 3.86 (0.4) 40 3.9 (0.39) 6.1 % -0.04 [ -0.21, 0.13 ]
Total (95% CI) 156 151 100.0 % -0.10 [ -0.15, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.42, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Favours LLLT Favours placebo
(1) Forest plot of LLLT versus placebo showing lower sensory nerve latency in LLLT group
(2) Forest plot of LLLT versus placebo showing lower sensory nerve latency in LLLT group
(3) Forest plot of LLLT versus placebo showing lower sensory nerve latency in LLLT group
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Analysis 1.8. Comparison 1 Low-level laser therapy (LLLT) versus placebo, Outcome 8 Sensory nerve
velocity (m/s).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 1 Low-level laser therapy (LLLT) versus placebo
Outcome: 8 Sensory nerve velocity (m/s)
Study or subgroup LLLT Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lazovic 2014 (1) 40 41.81 (10.12) 39 36.56 (9.79) 48.5 % 5.25 [ 0.86, 9.64 ]
Tascioglu 2012 40 33.63 (7.48) 20 35.69 (6.34) 51.5 % -2.06 [ -5.68, 1.56 ]
Total (95% CI) 80 59 100.0 % 1.48 [ -5.68, 8.65 ]
Heterogeneity: Tau2 = 22.50; Chi2 = 6.34, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Favours LLLT Favours placebo
(1) Forest plot of LLLT versus placebo showing no significant difference of sensory nerve velocity between LLLT and placebo
Analysis 2.1. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 1 Symptom
Severity Score.
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 1 Symptom Severity Score
Study or subgroup LLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Saeed 2012 (1) 50 -0.44 (0.18) 50 -0.87 (0.18) 98.9 % 0.43 [ 0.36, 0.50 ]
Tikiz 2013 13 2.3 (1.1) 14 1.8 (0.6) 1.1 % 0.50 [ -0.18, 1.18 ]
Total (95% CI) 63 64 100.0 % 0.43 [ 0.36, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 12.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Forest plot of LLLT versus placebo showing higher SSS in LLT group
Analysis 2.2. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 2 Functional Status
Scale.
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 2 Functional Status Scale
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Saeed 2012 (1) 50 -0.4 (0.17) 50 -0.75 (0.12) 99.3 % 0.35 [ 0.29, 0.41 ]
Tikiz 2013 (2) 13 2.2 (1) 14 1.9 (0.8) 0.7 % 0.30 [ -0.39, 0.99 ]
Total (95% CI) 63 64 100.0 % 0.35 [ 0.29, 0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 11.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Favours LLLT Favours ultrasound
(1) Forest plot of LLLT versus USS showing higher FSS (worse function) in LLLT group
(2) Forest plot of LLLT versus placebo showing higher FSS (worse function) in LLLT group
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Analysis 2.3. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 3 Visual analogue
score.
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 3 Visual analogue score
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 (1) 25 -2 (1.3) 25 -6.3 (1.6) 36.0 % 4.30 [ 3.49, 5.11 ]
Saeed 2012 50 -2.6 (1.07) 50 -4.9 (1.46) 38.2 % 2.30 [ 1.80, 2.80 ]
Tikiz 2013 13 3.18 (2.7) 14 1.71 (2.16) 25.8 % 1.47 [ -0.38, 3.32 ]
Total (95% CI) 88 89 100.0 % 2.81 [ 1.21, 4.40 ]
Heterogeneity: Tau2 = 1.67; Chi2 = 19.03, df = 2 (P = 0.00007); I2 =89%
Test for overall effect: Z = 3.45 (P = 0.00057)
Test for subgroup differences: Not applicable
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Favours LLLT Favours ultrasound
(1) Forest plot of LLLT versus USS showing higher VAS (pain) in LLLT group
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Analysis 2.4. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 4 Grip strength
(kg).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 4 Grip strength (kg)
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 (1) 25 2.16 (1.88) 25 4 (2.19) 77.1 % -1.84 [ -2.97, -0.71 ]
Tikiz 2013 13 18.3 (9.4) 14 16 (6.3) 22.9 % 2.30 [ -3.78, 8.38 ]
Total (95% CI) 38 39 100.0 % -0.89 [ -4.30, 2.52 ]
Heterogeneity: Tau2 = 3.59; Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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(1) Forest plot of LLLT versus USS showing no significant difference of grip strength between LLLT and USS group
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Analysis 2.5. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 5 Motor nerve
latency (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 5 Motor nerve latency (ms)
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 (1) 25 -0.2 (0.2) 25 -1.1 (0.5) 41.1 % 0.90 [ 0.69, 1.11 ]
Saeed 2012 50 -0.18 (0.13) 50 -0.8 (0.23) 47.8 % 0.62 [ 0.55, 0.69 ]
Tikiz 2013 13 4.33 (0.8) 14 4.8 (1.5) 11.1 % -0.47 [ -1.37, 0.43 ]
Total (95% CI) 88 89 100.0 % 0.61 [ 0.27, 0.95 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 11.97, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 3.55 (P = 0.00039)
Test for subgroup differences: Not applicable
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Favours LLLT Favours ultrasound
(1) Forest plot of LLLT versus USS showing motor nerve latency in LLLT group
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Analysis 2.6. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 6 Sensory nerve
latency (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 6 Sensory nerve latency (ms)
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 25 0.1 (1.1) 25 -0.8 (1) 27.0 % 0.90 [ 0.32, 1.48 ]
Saeed 2012 (1) 50 -0.07 (0.07) 50 -0.54 (0.28) 50.4 % 0.47 [ 0.39, 0.55 ]
Tikiz 2013 13 3.7 (0.7) 14 3.9 (1.1) 22.6 % -0.20 [ -0.89, 0.49 ]
Total (95% CI) 88 89 100.0 % 0.43 [ -0.01, 0.87 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.71, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours LLLT Favours ultrasound
(1) Forest plot of LLLT versus USS showing no significant difference of sensory nerve latency between LLLT and USS group
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Analysis 2.7. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 7 Motor amplitude
(mV).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 7 Motor amplitude (mV)
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 25 1.1 (2.9) 25 3.6 (1.5) 68.6 % -2.50 [ -3.78, -1.22 ]
Tikiz 2013 (1) 13 9.1 (3.9) 14 9.7 (2.9) 31.4 % -0.60 [ -3.21, 2.01 ]
Total (95% CI) 38 39 100.0 % -1.90 [ -3.63, -0.18 ]
Heterogeneity: Tau2 = 0.71; Chi2 = 1.64, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Favours ultrasound Favours LLLT
(1) Forest plot of LLLT versus USS showing lower motor amplitude in LLLT group
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Analysis 2.8. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 8 Sensory latency -
preanalysis (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 8 Sensory latency - preanalysis (ms)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 0.9 (0.297321) 27.0 % 0.90 [ 0.32, 1.48 ]
Saeed 2012 0.47 (0.040817) 50.4 % 0.47 [ 0.39, 0.55 ]
Tikiz 2013 -0.2 (0.352308) 22.6 % -0.20 [ -0.89, 0.49 ]
Total (95% CI) 100.0 % 0.43 [ -0.01, 0.87 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.71, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Low-level laser therapy (LLLT) versus ultrasound, Outcome 9 Sensory latency,
intracluster correlation coefficient 1.00 (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 2 Low-level laser therapy (LLLT) versus ultrasound
Outcome: 9 Sensory latency, intracluster correlation coefficient 1.00 (ms)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Bakhtiary 2004 0.9 (0.535) 0.6 % 0.90 [ -0.15, 1.95 ]
Saeed 2012 0.47 (0.040817) 99.1 % 0.47 [ 0.39, 0.55 ]
Tikiz 2013 -0.2 (0.69) 0.3 % -0.20 [ -1.55, 1.15 ]
Total (95% CI) 100.0 % 0.47 [ 0.39, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 11.57 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Low-level laser therapy (LLLT) versus steroid injection, Outcome 1 Motor
latency (ms).
Review: Low-level laser therapy for carpal tunnel syndrome
Comparison: 3 Low-level laser therapy (LLLT) versus steroid injection
Outcome: 1 Motor latency (ms)
Study or subgroup LLLT Ultrasound
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lucantoni 1992 20 4.86 (0.72) 20 4.95 (0.85) 48.9 % -0.09 [ -0.58, 0.40 ]
Soltani 2013 (1) 16 4 (0.7) 17 4 (0.7) 51.1 % 0.0 [ -0.48, 0.48 ]
Total (95% CI) 36 37 100.0 % -0.04 [ -0.39, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours LLLT Favours steroid injection
(1) Forest plot of LLLT versus steroid injection showing no significant difference of motor latency between LLLT and placebo
A P P E N D I C E S
Appendix 1. CENTRAL (Wiley) search strategy
Searched 9 December 2016
#1 “carpal tunnel syndrome”:ti,ab,kw
#2 ((nerve entrapmen* or nerve compression or entrapment neuropath*) and carpal)
#3 #1 OR #2
#4 “low-level light therapy”:ti,ab,kw
#5 “lasers”:ti,ab,kw
#6 laser or low-level or LLLT
#7 #4 OR #5 OR #6
#8 #3 AND #7
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Appendix 2. MEDLINE (Pubmed) search strategy
Searched 9 December 2016.
((((((((((carpal tunnel syndrome[Title/Abstract] OR median nerve[Title/Abstract] AND carpal[Title/Abstract]))) OR (((nerve entrap-
ment or nerve compression or entrapment neuropath*) and carpal [tiab])))) OR carpal tunnel syndrome[MeSH Terms])) AND ((low-
level light therapy[MeSH Terms]) OR “lasers”[MeSH Terms])) AND (laser [tiab] OR low-level [tiab]or LLLT [tiab])) AND (((ran-
domized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR
randomly [tiab] OR trial [tiab] OR groups [tiab])) AND humans [mh]))
Appendix 3. Embase (OvidSP) search strategy
Searched 9 December 2016
1. random* or factorial* or crossover* or cross over* or cross-over* or placebo* or doubl* blind* or singl* blind* or assign* or allocate*
or volunteer*.af.
2. exp crossover-procedure/ or exp double-blind procedure/ or exp randomized controlled trial/ or exp single-blind procedure/
3. 1. or 2.
4. low level laser therapy/
5. laser or low-level or LLLT.mp.
6, 4. or 5.
7. carpal tunnel syndrome/
8. (carpal tunnel syndrome or median nerve or ((nerve entrapment or nerve compression or entrapment neuropath*) and carpal)).mp.
9. 7. or 8.
10. 9. and 6. and 3.
Appendix 4. Web of Science Core Collection search strategy
Searched 9 December 2016
(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-analys*)
AND (carpal tunnel syndrome OR ((“nerve entrapment” or “nerve compression” or “entrapment neuropath*”) AND carpal)) AND
(low-level light therapy OR lasers OR (laser or low-level or LLLT))
Appendix 5. US National Institutes for Health Clinical Trials Registry search strategy
Searched 9 December 2016
(carpal tunnel syndrome OR ((“nerve entrapment” or “nerve compression” or “entrapment neuropath*”) and carpal)) AND (low-level
light therapy OR lasers OR (laser or low-level or LLLT))
Appendix 6. WHO International Clinical Trials Registry Platform search strategy
Searched 9 December 2016
(carpal tunnel syndrome OR ((“nerve entrapment” or “nerve compression” or “entrapment neuropath*”) and carpal)) AND (low-level
light therapy OR lasers OR (laser or low-level or LLLT))
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C O N T R I B U T I O N S O F A U T H O R S
IR: designed review; developed search strategy; undertook search of studies; screened search results; organised retrieval of papers;
screened retrieved papers against inclusion/exclusion criteria; appraised risk of bias of papers; extracted data from papers; wrote to study
investigators for additional information; summarised risk of bias of studies; compiled summary of comparisons, tables of included,
excluded, awaiting and ongoing studies; entered data into Review Manager 5; performed analysis of data; interpreted findings; wrote
review.
HS: screened search results; screened retrieved papers against inclusion/exclusion criteria; appraised risk of bias of papers; extracted data
from papers; checked data entered into Review Manager 5 by IR, summarised risk of bias of studies.
HR: appraised risk of bias of papers; extracted data from papers; summarised risk of bias of studies.
KSG: advised on protocol, review process, search strategies, and data analysis; contributed to writing of review.
D E C L A R A T I O N S O F I N T E R E S T
IAR: none known.
HS: none known.
HR: none known.
KSG: none known.
S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The random-effectsmodel was adopted for all outcomes as themore conservative effectsmodel, regardless of heterogeneity.We expressed
results for continuous outcomes as mean differences with 95% confidence intervals where trials used the same scale, as opposed to
standardised mean differences for all outcomes. Cochrane Neuromuscular states preference within published guidance for one primary
outcome and up to five secondary outcome measures. As such, primary and secondary outcomes were altered to comply with this;
however, all outcomes from the initial protocol have been included within the text to avoid selective reporting bias.
The protocol for the review stated that all outcomes would be included in a ’Summary of findings’ table. For this Cochrane Review, we
selected key outcomes for inclusion in ’Summary of findings’ tables. We produced tables for all comparisons for which any numerical
data were available. Within each ’Summary of findings’ table, we listed the specified outcomes whether or not the included studies
measured or reported them.
We intended to perform subgroup analyses for sex, age, severity of CTS symptoms, and studies at high versus studies at low risk of
bias. However, sufficient information was not available for these subgroup analyses.
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